POPULARITY
Categories
The American Academy of Pediatrics released new vaccine recommendations that directly oppose guidance from the HHS – insisting on COVID-19 vaccinations in babies as young as 6 months. Pathologist Dr. Ryan Cole & Dr. Kelly Victory reveal how the AAP has been captured by Big Pharma interests. The organization's top donors, listed on their own website, are Merck, Moderna, Pfizer, and Sanofi: the 4 pharma companies that “make virtually every vaccine on the CDC recommended childhood vaccine schedule.” HHS Secretary Robert F. Kennedy Jr. issued a stern warning in response: “AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act.” Dr. Ryan Cole is a board-certified pathologist trained at Mayo Clinic with subspecialty in dermatopathology from Columbia University. He holds a PhD in virology and immunology and directed a medical laboratory in Idaho for 20 years. He testifies globally on Covid policy and medical freedom. Follow at https://x.com/drcole12 Dr. Kelly Victory is Chief of Emergency & Disaster Medicine at The Wellness Company. A trauma and emergency specialist with over 30 years of experience, she served as Chief Medical Officer for Fortune 500 companies and is an alumna of Harvard's National Preparedness Leadership Initiative. More at https://x.com/DrKellyVictory 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices
Jordan Sather and Nate Prince return with another hard-hitting episode of MAHA News, diving into the week's biggest health and freedom stories. They kick things off with the Pete and Bobby Challenge, where Pete Hegseth and RFK Jr. put their strength to the test in a push-up and pull-up competition that has everyone talking. From there, the hosts shift into the serious implications of glyphosate spraying in Canada and the broader dangers of genetically engineered crops, highlighting how hidden RNA tinkering in food could impact human genetics and health. The discussion then takes aim at the American Academy of Pediatrics, which is under fire for its push to remove vaccine exemptions and its continued cozy ties with big pharma giants like Pfizer, Merck, and Moderna. RFK Jr.'s sharp rebuke of the AAP sparks debate about liability, childhood vaccine schedules, and health freedom. With side conversations on raw milk legalization, natural detox strategies, and the cultural psyop of green lawns, this episode weaves humor, practicality, and blunt truth into an engaging exploration of health sovereignty.
After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance. Among U.S. pharma heavyweights, J&J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies. Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck’s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics. To learn more about the topics in this episode: Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year The battle of the obesity drug heavyweights 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview See omnystudio.com/listener for privacy information.
Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.
After some years developing websites and interactive and digital marketing projects, Guillem joined Merck in 2009, and he has been always related to digital marketing projects on the business side. Since 2020 Guillem has been driving the Social Selling initiative for Merck Life Science, focusing on Social Scouting with LinkedIn Sales Navigator, Social Listening and Employee Advocacy, to help Sales teams be more effective by using social channels to uncover new business opportunities. His work with using Chat CPT to support employee content has been truly inspiring with some great results. Folllow him on Linkedin for more https://www.linkedin.com/in/guillemcardenal/ Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Sumanta (Monty) Pal and Dr. Arielle Elkrief discuss the clinical relevance of the gut microbiome in cancer immunotherapy and the importance of antibiotic stewardship, as well as interventions currently being explored to treat gut dysbiosis and optimize immunotherapy response. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hi everyone, I'm Dr. Monty Pal, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist. I'm a professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today we're here to discuss one of my favorite topics, which is the gut microbiome. It's almost hard to avoid the gut microbiome nowadays if you look at medical literature within oncology. It's an emerging phenomenon, but there are a couple of individuals that I would really define as pioneers in the field. And one of them is actually with me today, Dr. Arielle Elkrief, to discuss the clinical relevance of the gut microbiome, particularly amongst patients receiving immunotherapy, although I imagine our conversation today will take many twists and turns. Arielle is an assistant professor and clinician scientist in the Department of Oncology at the University of Montreal, and she is co-director of the CHUM Microbiome Center there. FYI for the listeners, we have our full disclosures in the transcript of this episode. Arielle, thank you so much for joining us today. Dr. Arielle Elkrief: Thanks so much, Monty. This is going to be amazing. Dr. Sumanta (Monty) Pal: Well, I have to tell you what sort of inspired me to bring you on as a guest. It was one of many things, but it was this really terrific ASCO Educational [Book] article that you wrote. Now, I have to tell you, I've read all the articles sort of cover to cover in the book, and they're always a wonderful primer, so if our audience is studying for board research or something of that sort, it's a terrific resource to go through. I have to tell you, this piece on the gut microbiome that you wrote is nothing short of a masterpiece. If you read this cover to cover, it's actually going to give you, I think, a sense of the current state and future state of the field. I wanted to start by just sort of beginning with sort of the origin story for a lot of this, which is this association between the gut microbiome and immunotherapy response. This takes us back several years to this pivotal series of papers in Science. Maybe you could walk our audience through that. Dr. Arielle Elkrief: Absolutely. Well, thank you so much for your kind words about the ASCO [Educational] Book. It was a team effort with a lot of key opinion leaders in the field, so I'm really glad to learn that you've liked it. Moving backwards in terms of how we came to understand that the gut microbiome is essential to priming a response to cancer immunotherapy actually goes back to 2015 and seminal papers that looked at what happens when we take mice that are germ-free mice that have never been exposed to a microbiome. These are mice that are born by cesarean section and essentially live in a bubble. And when we give those mice tumors and treat them, in the first papers with anti-CTLA-4 treatment, we realized that these antibodies don't work at all. And that was the first observation that the presence of a gut microbiome was essential to mounting an anti-cancer immune response. When we supplemented those same mice with beneficial bacteria or feces from responder patients, we were able to restore the response to immunotherapy. And so those were really the first preclinical observations that made us understand the critical role of the microbiome in immunotherapy response. Moving a little bit in the future, we examined the fecal microbiome composition using shotgun metagenomic sequencing in different cohorts of patients with solid tumors, namely lung cancers, kidney cancers, and also skin tumors like melanoma, and found that patients who responded to immunotherapy had a distinct microbiome that was characterized by beneficial bacteria compared to patients who experienced resistance to immunotherapy that had a dysbiotic or diseased microbiome. Dr. Sumanta (Monty) Pal: So, you know, it's interesting, these techniques that we're using to sequence the gut, they're a little bit different. So I wonder if you can give the audience a quick primer on these techniques that you're so well versed in, shotgun metagenomic sequencing, 16S rRNA sequencing. If you had to describe this in 30 seconds, which is a tall task, how would you do that? Dr. Arielle Elkrief: That's a tall task. Much of what we know about the microbiome initially came from a technique called 16S rRNA sequencing. This is a technique that amplifies the 16S region and basically tells you at the genus level what's going on at the level of bacterial composition. This technique is fast, relatively cheap, and can be performed on a laptop computer, which is excellent. The problem is that it's prone to a lot of technical variations. Different primers might give you different results, and you're really limited at the genus resolution. You can't get a good resolution in terms of species, and we're learning that different species from the same genus might have different physiological properties, and the same thing goes at the strain level. So when we really zone in and look at inter-species changes, we're seeing that these actually have specific functions in the host. So that brings us to metagenomic sequencing, which is a whole genome sequencing, next-generation sequencing based method that looks at the whole composition and gives you information not only on bacteria, but you might also get fungal and viral properties. You can zoom in on the strain level. You can also get functional output, so we can examine what the metabolic properties of specific species or strains might look like. The negative aspects of shotgun metagenomic sequencing is that it takes a lot of computational power in order to analyze the results and it might take a little bit longer. And certainly, within the clinical setting, not something that's feasible yet. And that brings us to more novel point-of-care biomarker tools that we've collaborated in developing along with Dr. Laurence Zitvogel and Dr. Lisa Derosa at Gustave Roussy, that learning from the shotgun metagenomics results designed a probe using quantitative PCR which looks for this specific bacteria we know to be important and developed a ratio of harmful bacteria to beneficial bacteria. This is called the TOPOSCORE, and it actually is able to predict quite nicely the response to immunotherapy using a stool sample and a really good turnaround time of almost 72 hours. Dr. Sumanta (Monty) Pal: That was a perfect overview and a lot of information in a short amount of time. It also makes you take out your high school biology textbooks, doesn't it, to understand that the bacterial ribosome, right, is a different size and shape, and that's what we're sequencing here. But these techniques I think are incredibly important, and I'm glad you actually discussed this, this RT-PCR based strategy of calculating the TOPOSCORE. It lends itself to this phenomenon of dysbiosis, and I think for our audience, that's going to be an important term to understand as time goes on. There's the normal healthy gut and then there's this phenomenon of dysbiosis, which is, I guess, simply put, an unhealthy gut. But tell us about, you know, how often you see dysbiosis in a cancer patient, maybe versus a normal healthy adult. Dr. Arielle Elkrief: So, I think we can split up your question into two parts. One is we know from cohort studies and population level-based studies that the microbiome of patients with cancer is distinct from healthy patients or healthy people. And we know that because of the global composition. We also think that there are diversity metrics that lend themselves to being described as dysbiotic. But we do know that the microbiome of people with cancer is distinct from healthy volunteers. That's the first point. In terms of how frequently dysbiosis occurs in patients with cancer, it's not very well defined. We know that even among healthy people, there is a certain level of dysbiosis. Laurence in her talk mentioned that to be about 10% to 20%. And the other fascinating component is that when we're thinking about dysbiosis and the cancer associated microbiome, in terms of the species that are enriched, it's quite striking that a lot of these dysbiotic or negative bacteria are also found to be enriched in patients with metabolic disease, like cardiovascular disease, for example. And so it's unclear if dysbiosis is the cause or consequence, but there definitely seems to be a general pattern of disease when looking at the microbiome compared to healthy people. Dr. Sumanta (Monty) Pal: That's interesting. So, I'll tell you, my second favorite portion of your article, and I'll tell you my favorite portion as well in the context of this podcast, but my second favorite part was the section around antibiotic stewardship. You know, the utilization of antibiotics in a very pragmatic fashion amongst our patients. Can you describe why that's so critical in the context of the microbiome? Dr. Arielle Elkrief: Antibiotics can disrupt the gut microbiome composition. We know this from mouse studies, but also cohort studies of patients that are exposed to antibiotics. And most importantly, we know that patients who are exposed to antibiotics, either before or during the immunotherapy period, have significantly worse progression-free survival and overall survival to immunotherapy. And this is true for immunotherapy in the monotherapy setting, but also when combined with chemotherapy. What's striking is that when we look at patients who are just treated with chemotherapy, we don't see the negative outcome of antibiotics on outcome and progression-free survival and overall survival, suggesting that the negative impact of antibiotics on outcomes is really specific to immunotherapy backbones. The other important point is that this negative signal is maintained even after adjusting for standard prognostic variables in the specific malignancies that we're looking at. And then most importantly, at the mechanistic level, we were able to actually pinpoint the mechanism behind this antibiotic related dysbiosis. And we see this with a bloom of negative bacteria which induces a loss of MAd-CAM, which is an endothelial gut checkpoint immune marker, and that causes an efflux of immunosuppressive T cells, which are usually in the gut, to go straight into the tumor where they make the tumor unamenable to an immunotherapy response. And so now we finally have the mechanism as to why antibiotics are harmful and why we need to practice antibiotic stewardship. Dr. Sumanta (Monty) Pal: And just to be clear for the audience, I mean, if a patient needs antibiotics, they need antibiotics. But perhaps it just suggests that, and we have, I suppose, this predilection as oncologists, just for the minor cold or cough or what have you, we maybe should be a little bit more cognizant of whether or not antibiotics are truly necessary. Is that fair? Dr. Arielle Elkrief: Absolutely. So what we're advocating for is antibiotic stewardship, and this is the clear recommendation that we can make. So that means confirming a bacterial infection. If it's there and antibiotics are indicated, to choose the most narrow spectrum for the shortest course and constantly re-evaluate the indication of antibiotics. And of course, we need to work with our colleagues in infectious diseases who've done incredible work in antibiotic stewardship. And all along this process we also need to be mindful of other medications and polypharmacy, such as proton pump inhibitors or narcotics, for example, we think that these other medications which are frequently prescribed in our cancer population can also potentially have negative impacts on the microbiome and immunotherapy response. Dr. Sumanta (Monty) Pal: I think that's a terrific summary and big guidance for the audience. I promised you I'd tell you my favorite part of your article, and this is this huge table. I think the table is two and a half pages long, if I remember correctly, but it's an awesome table, and I highly recommend our audience to check this out. It lists literally every therapeutic trial for the microbiome under the sun. And so it begins with the approach of fecal microbiota transplant, which I'm going to ask you to tell us about in a second, but it also hinges on a lot of really cool sort of novel therapies, live bacterial products, mixes of different microbial products. Maybe take us through this whole approach of FMT (fecal microbiota transplantation). I actually wasn't aware of the dozens of trials that you listed there in this space. It seems like it's a very active area of research. Dr. Arielle Elkrief: Definitely. So, as you alluded to, FMT or fecal microbiota transplantation is the most well studied and direct way to modify the patient's microbiome. This technique aims to replace the patient's dysbiotic microbiome with that of a healthy microbiome, either from a healthy donor volunteer that's been heavily screened, or from a patient who experienced response to immunotherapy. And, as three landmark studies so far that have been published demonstrated the potential of FMT to reduce primary resistance or secondary resistance to immunotherapy, and this has been in melanoma. We also recently reported on the results of our FMT-LUMINate trial, which looked at patients with lung cancer and melanoma. Once again, FMT, when combined with immunotherapy was safe and led to a higher proportion of responses than we would normally expect. We're now also looking at randomized trials that have come out. So the first being the TACITO trial in kidney cancer, which compared FMT plus pembrolizumab and axitinib to placebo in patients with RCC, and again, FMT was safe and feasible and also led to an increased progression-free survival at one year, meeting the study's primary endpoint. And so, so far, there's a wealth of data really showing the promise of FMT when combined with immunotherapy, and we're now in the process of conducting larger randomized trials, including in melanoma with the CCTG (Canada Cancer Trials Group) in our ME17 or Canbiome2 trial, where we're going to be enrolling 128 patients with metastatic melanoma to receive FMT and standard of care immunotherapy compared to standard of care immunotherapy alone. Dr. Sumanta (Monty) Pal: You're very humble, so I've got to highlight for our audience. This was a mega grant that Arielle received to fund really the largest prospective exploration of FMT that will exist to date. So I'm really excited about that. I wish this was something we could participate in stateside. Before we jump into the other approach, which is live bacterial products and mixes thereof, where do you see FMT going? I think that one of the perceived challenges with FMT is that it's hard to implement, right? You need to have a really robust framework when it comes to gastroenterology, the preparation's challenging. Is there a way to envision FMT use being more generalized? Dr. Arielle Elkrief: Those are great questions. So we're lucky in Canada to work with pioneers in FMT, Michael Silverman, Saman Maleki, and John Lenehan in London, Ontario, who had this really robust FMT healthy donor screening program, which literally screens for every pathogen under the sun, and we haven't had any problems with feasibility or implementing FMT in Canada. But I think that once we're going to hopefully start doing larger scale, randomized phase three studies, that we might run into problems with scalability. And I think also with regards to reproducibility, and that's the feedback that we're getting from some regulatory authorities, especially at the level of the FDA, where there are some concerns around inter- and intra-donor variability because, of course, we can't guarantee that every fecal sample is going to be the same. So that has really pushed the field to think about other strategies, such as live biotherapeutic products which take modified FMT or bacteria from stools from either healthy donors or from responder patients and basically turn them into drugs that are regulated as drugs and can then be studied in the context of investigational new drugs or products. Dr. Sumanta (Monty) Pal: I like this and, you know, I do think that there's a future for it. We just have to kind of put our heads together and figure out how to get over all of these logistical hurdles, but, you know, I agree, I think your group and others have demonstrated, especially with this trial that you're fanning out all throughout Canada, that it can potentially be done. This is a topic that could probably go on for another couple of hours, right, especially based on the size of the table that you put together in this brilliant article, but tell us about live bacterial products or LBPs, as we call them these days. What's the current status, what's the future there? And maybe I'll give you less than two minutes here, although again, I realize it's a two-hour topic. Dr. Arielle Elkrief: You're probably better suited to speak about that because you've been one of the pioneers in terms of this. So we can think about LBPs in terms of single strain organisms, like CBM588 for an example, which your group did some amazing work in showing that, in a randomized setting, that this led to better responses than we would expect compared to just work with controls. We also know that LBPs can have multiple strains, up to 30. We're collaborating with a company called Cannabis Bioscience that is actually working on much larger communities of consortia. And so we're really excited about the direction that that's taking in terms of taking these LBPs and developing them from the drug perspective. In addition to LBPs, we know that there are other ways that we can change the microbiome, notably prebiotics, which are compounds which can have a beneficial impact on the microbiome. And one of these is camu camu, which I know your group is leading a clinical trial looking at camu camu and kidney cancer, and we're excited to see how that compares to FMT or LBPs, because that might be a potentially scalable alternative. Dr. Sumanta (Monty) Pal: That's awesome. What a terrific overview, and that was less than two minutes. I don't know how you did it. That's terrific. Arielle, this has been such an insightful conversation. I just want to thank you for, again, a terrific article in the ASCO Educational Book. I highly recommend all of our listeners to go there and check it out, and also for sharing all these terrific insights on the podcast today. Dr. Arielle Elkrief: Thank you so much, Monty. Dr. Sumanta (Monty) Pal: And thanks to our listeners, too. If you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Sumanta (Monty) Pal @montypal Dr. Arielle Elkrief Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Arielle Elkrief: Honoraria: AstraZenica, Bristol-Myers Squibb, Merck, EMD Serono Consulting or Advisory Role: Bristol-Myers Squibb Research Funding (Inst.): Kanvas Bioscience, AstraZeneca, Merck Other Relationship: Royal College of Surgeons and Physicians of Canada, Cedar's Cancer Center (Henry R. Shibata Fellowship), Canadian Institutes of Health Research (CIHR)
There aren't many Ivy League professors as bold as Dave Collum. It's amazing he still has a job. (00:00) How Collum Predicted the 2008 Financial Crisis (11:00) Collum's Mission to Uncover the Truth About Covid (19:36) Government Experiments Being Conducted on Foster Care Children (24:17) What's the Truth About Diddy? (34:07) What's the Truth About the Assassination Attempt on Donald Trump? (1:00:45) Are We Being Purposefully Distracted From Things That Actually Matter? (1:12:04) The Real Dangers of AI Dave Collum is a professor of organic chemistry at Cornell University, where he earned his BS in biology and later returned after completing his PhD in chemistry at Columbia. A former department chair and 20-year associate editor of The Journal of Organic Chemistry, Dave has also consulted for major pharmaceutical companies including Merck, Pfizer, and Amgen. Outside of academia, he's known for his sharp, contrarian takes on politics, economics, and culture—often shared via his unfiltered X account (@DavidBCollum), frequent podcast appearances, and his widely read annual “Year in Review” at Peak Prosperity. He's also coached collegiate gymnastics and taekwondo and has been featured in outlets like The Wall Street Journal, Rolling Stone, and The Federalist but usually on topics far removed from chemistry. Paid partnerships with: Dutch: Get $50 a year for vet care with Tucker50 at https://dutch.com/tucker Liberty Safe: Visit https://LibertySafe.com to find a dealer and learn more Beam: Get 30% off for a limited time using the code TUCKER at https://ShopBeam.com/Tucker Learn more about your ad choices. Visit megaphone.fm/adchoices
New: Valora - Your AI Business Coach Turn the wisdom from this episode into practical actions for your business in minutes. Click here now to access the tool > How to Lead with Quiet Confidence and Create Partnerships that Thrive Does it sometimes feel as though the workplace, or business world, was designed for the loudest voices, not for you? In this episode of The Brilliant Business Book Festival, I'm joined by Jennifer Kahnweiler, author of The Introverted Leader (3rd Edition): Building on Your Quiet Strength, and several other books that change the business game. Her work shines a light on what so many of us have felt: introverts aren't less capable, they simply lead differently. And when they're allowed to do so, the results can be extraordinary. What follows isn't just a recap of our conversation. It's a deeper dive into why introversion is a leadership advantage, how introverts and extroverts can form “genius opposites” partnerships, and how practical tools like delegation and preparation can transform how we show up at work. You'll learn how understanding your natural wiring can help you prepare, communicate, and collaborate more powerfully, without pretending to be someone you're not. If you've ever felt overlooked in meetings, frustrated by fast-paced demands, or unsure how to delegate without losing your standards, this conversation will give you tools, strategies, and confidence to lead on your own terms. Prefer to WATCH instead of read? Visit: https://www.youtube.com/@melittacampbell/podcasts “Quiet leaders aren't less capable — they're often more prepared, more observant and more trusted.” - Jennifer Kahnweiler Why Introversion is a Leadership Strength For too long, introversion has been cast as something to overcome. “Speak up more.” “Be more confident.” “Network like extroverts.” But Jennifer reminds us: introversion isn't a flaw. It's a foundation. Introverted leaders thrive because they bring qualities that today's organisations desperately need: Preparation: the ability to walk into a room having thought through angles, questions, and next steps. Deep listening: a skill that makes colleagues and clients feel truly heard. Meaningful connection: not surface-level networking, but genuine one-to-one or small group relationships that last. Think of it like gardening. Extroverts may scatter seeds widely, covering ground quickly. Introverts plant fewer seeds, but tend and water them with patience … leading to stronger, longer-lasting growth. When introverts stop trying to keep up with the loudest voices and instead honour their natural wiring, leadership begins to feel more natural, more energising, and more effective. Making the Most of “Genius Opposites” One of Jennifer's most fascinating frameworks is what she calls “genius opposites”: introverted–extrovert partnerships that, when nurtured properly, create exponential results. Through her research, she developed the ABCDE model for making these partnerships thrive: A – Accept the Alien: stop trying to change your partner; embrace their difference. B – Bring on the Battles: don't avoid conflict, air it out early before resentment builds. C – Cast the Character: put people in roles where their strengths shine (the extrovert waving people down at a trade show; the introvert taking them deeper once they're at the booth). D – Destroy the Dislike: you don't have to be best friends, but you do need mutual respect, and a little humour goes a long way. E – Each Can't Offer Everything: clients and colleagues benefit when both voices are present; difference leads to richer solutions. The metaphor here is a pair of rowers in a boat. If both row on the same side, you go in circles. But when you learn to pull in sync from opposite sides, you glide forward faster and straighter than you ever could alone. “The right introvert–extrovert partnership doesn't add up, it multiplies.” - Jennifer Kahnweiler Speaking Up — Without Being Loud One of the biggest frustrations introverts share is being overlooked in meetings. You pause to reflect before speaking, and suddenly someone else has jumped in. Silence gets misread as disinterest. But Jennifer offers strategies that allow introverts to be heard without forcing themselves to “perform”: Prepare key points ahead of time so you can contribute with clarity. Ask for reflection time (“I'd like to think about this and come back with a response tomorrow”). Follow up in writing with a synthesis of ideas, often more valuable than what's said in the room. Brené Brown has even built reflection breaks into her team's meetings, so introverts (including herself) have space to process ideas before decisions are made. A simple but profound reminder that influence doesn't always happen in the room; it happens in the follow-up too. Delegation Without the Guilt Many introverts struggle with delegation — worried that tasks won't be done to their standard, or that they'll burden others. But holding on to everything creates bottlenecks, exhaustion and stalled growth. Jennifer reframes delegation as a gift, not a burden. By handing over tasks: You free space for your strategic thinking, the work only you can do. You give others the opportunity to learn and grow. You prevent burnout, ensuring you show up as your best self. Think of delegation like passing a torch in a relay race. You're not abandoning the run; you're ensuring the team as a whole keeps moving forward faster. The Quiet Confidence Advantage If you take only one thing from Jennifer's research and our conversation, let it be this: Introversion is not just “enough” — it's an advantage. By honouring your natural strengths, partnering wisely with complementary styles, and creating environments where quieter voices are respected, you don't just survive in leadership — you thrive. And perhaps the bigger invitation is this: what if we stopped assuming leadership must look a certain way, and instead embraced the full spectrum of how people naturally show up? The result wouldn't just be fairer, it would be far more effective. Final Thought to Reflect On? What could shift for you if you stopped trying to “keep up” with the loudest voices, and instead led in the way only you can? Want to explore what this could look like for you? Learn more about the ways you can work with Melitta Campbell to uncover your Value Sweet Spot to market, sell and grow your business confidently, and always on your terms. Working with Melitta > About Jennifer Jennifer B. Kahnweiler, PhD, is a bestselling author and one of the top global leadership speakers on introverts in the workplace. Her pioneering books, The Introverted Leader, Quiet Influence, The Genius of Opposites, and Creating Introvert-Friendly Workplaces have been translated into 18 languages. The Introverted Leader was named one of the top 5 business books by The Shanghai Daily. Jennifer has partnered with leading organizations like Amazon, Merck, Kimberly Clark, NASA, Bosch, and the US Centers for Disease Control. She has over 12 years experience delivering online presentations and courses. She has delivered keynotes from Singapore to Spain. Her engaging presentations to diverse audiences blend research with provocative examples and practical tools. Jennifer has been featured in The Wall Street Journal, Forbes, and The New York Times and has appeared as a guest on over 100 podcasts. Jennifer holds the Certified Speaking Professional designation, awarded to a small percentage of speakers, and is proud to serve as a mentor to many professional women. She received her PhD in counseling and organizational development from Florida State University and her degrees in sociology and counseling from Washington University, St. Louis. A native New Yorker, Jennifer calls Atlanta, GA home. Read Jennifer's Book: The Introverted Leader (3rd Edition): Building on Your Quiet Strength Connect with Jennifer Website LinkedIn About Your Host, Melitta Campbell Melitta Campbell is an award-winning business coach, TEDx speaker, author of A Shy Girl's Guide to Networking and founder of the Dream Clients Club. Through her Value WhisperingTM Blueprint, she helps introverted female entrepreneurs build quietly impactful businesses that grow through clarity, trust, and alignment. Learn more about working with Melitta here Loved this episode? Turn your Insight into Action with Valora Valora is the podcast's new AI Business Coach. Answer three short questions and she'll translate your responses into simple, practical actions you can take this week to grow your business. Click here now to access Valora > You May Also Enjoy... Get a PhD in You: A Course in Miraculous Self-Discovery The Go-Giver: A Little Story About a Powerful Business Idea The Common Path To Uncommon Success More Heart, Less Hustle The Truth About Entrepreneurial Poverty (and how to avoid it) > More Podcast Episodes
The drug maker Merck recently announced its plans to start two new trials, known as the EXPrESSIVE program, testing a monthly pill for PrEP. A once-a-month PrEP pill holds great potential for the field. Even with daily pills, a monthly ring, or long acting injectables such as cabotegravir and recently FDA-approved lenacapavir, there'll be people who can't find what they really need for prevention. For advocates who follow prevention, there's a lot to know about these trials, and powerful lessons to learn about Good Participatory Practice (GPP) and impactful involvement of stakeholders—especially community—in research. GPP has been a cornerstone of the process of design and protocol development for the EXPrESSIVE trials, and it doesn't stop there. This episode features Merck Senior Principal Scientist Rebeca Plank and AVAC's Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials.
Dominate C. diff! Learn to distinguish colonization from infection, select first-line therapies, and counsel patients on recurrence prevention and microbiome recovery. We're joined by IDSA past president and expert on foodborne and intestinal infections, Dr. Cindy Sears (Johns Hopkins University) for a comprehensive update on Clostridioides difficile (C. diff, Cdiff, CDAD, CDI). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 03:00 Guest bio and hobby 04:25 Case of Charles Fleur Fontaine 06:00 Risk factors and epidemiology 08:00 Antibiotic hierarchy of risk 10:00 Diagnosis, testing strategies 14:00 Defining severity 17:30 Treatment options 20:00 Microbiome recovery strategies 24:00 Probiotics and postbiotics 27:00 Infection control counseling 30:00 C. diff and colon cancer 32:00 Recurrent C. diff strategies 35:00 Why some FMT and bezlotoxumab were discontinued 38:00 Microbiota replacement therapies 43:00 Prophylaxis strategies 45:00 Future therapies and ongoing research 47:00 Audience Q&A 52:00 Outro Credits Written and Produced by: Matthew Watto, MD, FACP Cover Art and Infographic by: Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cynthia Sears MD Disclosures Dr. Sears reports no relevant financial disclosures. Dr. Williams financial relationships disclosed include a Merck grant or research support. This relationship has not ended. Sponsor: Mint Mobile This year, skip breaking a sweat AND breaking the bank. Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at mintmobile.com/CURB Sponsor: Panacea Financial Let Panacea Financial take the financial stress off your plate,so you can get back to doing what matters most. Visit panaceafinancial.com Sponsor: FIGS Get15% off your first order at wearfigs.com with the code FIGSRX
Dr. Hope Rugo and Dr. Kamaria Lee discuss the prevalence of financial toxicity in cancer care in the United States and globally, focusing on breast cancer, and highlight key interventions to mitigate financial hardship. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm your host, Dr. Hope Rugo. I'm the director of the Women's Cancer Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. Rising healthcare costs are causing financial distress for patients and their families across the globe. Patients with cancer report financial toxicity as a major impediment to their quality of life, and its association with worse outcomes is well documented. Today, we'll be discussing how patients with breast cancer are uniquely at risk for financial toxicity. Joining me for this discussion is Dr. Kamaria Lee, a fourth-year radiation oncology resident and health equity researcher at MD Anderson Cancer Center and a co-author of the recently published article titled, "Financial Toxicity in Breast Cancer: Why Does It Matter, Who Is at Risk, and How Do We Intervene?" Our full disclosures are available in the transcript of this episode. Dr. Lee, it's great to have you on this podcast. Dr. Kamaria Lee: Hey, Dr. Rugo. Thank you so much for having me. I'm excited to be here today. I also would like to recognize my co-authors, Dr. Alexandru Eniu, Dr. Christopher Booth, Molly MacDonald, and Dr. Fumiko Chino, who worked on this book chapter with me and did a fantastic presentation on the topic at ASCO this past year. Dr. Hope Rugo: Thanks very much. We'll now just jump into the questions. We know that rising medical costs contribute to a growing financial burden on patients, which has [GC1] [JG2] been documented to contribute to lower quality-of-life, compromised clinical care, and worse health outcomes. How are patients with breast cancer uniquely at risk for financial toxicity? How does the problem vary within the breast cancer population in terms of age, racial and ethnic groups, and those who have metastatic disease? Dr. Kamaria Lee: Breast cancer patients are uniquely at risk of financial toxicity for several reasons. Three key reasons are that breast cancer often requires multimodal treatment. So this means patients are receiving surgery, many receive systemic therapies, including hormonal therapies, as well as radiation. And so this requires care coordination and multiple visits that can increase costs. Secondly, another key reason that patients with breast cancer are uniquely at risk for financial toxicity is that there's often a long survivorship period that includes long-term care for toxicities and continued follow-ups, and patients might also be involved in activities regarding advocacy, but also physical therapy and mental health appointments during their prolonged survivorship, which can also add costs. And a third key reason that patients with breast cancer are uniquely at risk for financial toxicity is that the patient population is primarily women. And we know that women are more likely to have increased caregiver responsibilities while also potentially working and managing their treatments, and so this is another contributor. Within the breast cancer population, those who are younger and those who are from marginalized racial/ethnic groups and those with metastatic disease have been shown to be at an increased risk. Those who are younger may be more likely to need childcare during treatment if they have kids, or they're more likely to be employed and not yet retired, which can be disrupted while receiving treatment. And those who are racial/ethnic minorities may have increased financial toxicity due to reasons that exist even after controlling for socioeconomic factors. And some of these reasons have been shown to be increased risk of job or income loss or transportation barriers during treatment. And lastly, for those with metastatic breast cancer, there can be ongoing financial distress due to the long-term care that is needed for treatment, and this can include parking, transportation, and medications while managing their metastatic disease. Dr. Hope Rugo: I think it is really important to understand these issues as you just outlined. There has been a lot of focus on financial toxicity research in recent years, and that has led to novel approaches in screening for financial hardship. Can you tell us about the new screening tools and interventions and how you can easily apply that to clinical practice, keeping in mind that people aren't at MD Anderson with a bunch of support and information on this but are in clinical practice and seeing many, many patients a day with lots of different cancers? Dr. Kamaria Lee: You're exactly right that there is incredible nuance needed in understanding how to best screen for financial hardship in different types of practices. There are multiple financial toxicity tools. The most commonly used tool is the Comprehensive Score for Financial Toxicity, also known as the COST tool. In its full form, it's an 11-item survey. There's also a summary question as well. And these questions look at objective and subjective financial burden, and it uses a five-point Likert scale. For example, one question on the full form is, "I know that I have enough money in savings, retirement, or assets to cover the cost of my treatment," and then patients are able to respond "not at all" to "very much" with a threshold score for financial toxicity risk. Of course, as you noted, one critique of having an 11-item survey is that there's limited time in patient encounters with their providers. And so recently, Thom et al validated an abbreviated two-question version of the COST tool. This validation was done in an urban comprehensive cancer center, and it was found to have a high predictive value to the full measure. We note which two questions are specifically pulled from the full measure within the book chapter. And this is one way that it can be easier for clinicians who are in a busier setting to still screen for financial toxicity with fewer questions. I also do recommend that clinicians who know their clinic's workflow the best, work with their team of nurses, financial navigators, and others to best integrate the tool into their workflow. For some, this may mean sending the two-item survey as a portal message so that patients can answer it before consults. Other times, it could mean having it on the tablet that can be done in the clinic waiting room. And so there are different ways that screening can be done, even in a busy setting, and acknowledging that different practices have different amounts of resources and time. Dr. Hope Rugo: And where would people access that easily? I recognize that that information is in your chapter, or your article that's on PubMed that will be linked to this podcast, but it is nice to just know where people could easily access that online. Dr. Kamaria Lee: Yes, and so you should be able to Google ‘the COST measure', and then there is a website that also has the forms as well. So it's also beyond the book chapter, Googling ‘the COST measure', and then online they would be able to find access to the form. Dr. Hope Rugo: And how often would you do that screening? Dr. Kamaria Lee: So, I think it's definitely important that we are as proactive as possible. And so initially, I recommend that the screening happens at the time of diagnosis, and so if it's done through the portal, it can be sent before the initial consult, or again, however, is best in the workflow. So at the time of diagnosis and then at regular intervals, so throughout the treatment process, but then also into the follow-up period as well to best understand if there's still a financial burden even after the treatments have been completed. Dr. Hope Rugo: I wonder if in the metastatic setting, you could do it at the change of treatment, you know, a month after somebody's changed treatment, because people may not be as aware of the financial constraints when they first get prescribed a drug. It's more when you hear back from how much it's going to cost. And leading into that, I think it's, what do you do with this? So, you know, this cost conversation is really important. You're going to be talking to the patient about the cost considerations when you, for example, see that there are financial issues, you're prescribing treatments. How do we implement impactful structured cost conversations with our breast cancer patients, help identify financial issues, and intervene? How do we intervene? I mean, as physicians often we aren't really all that aware, or providers, of how to address the cost. Dr. Kamaria Lee: Yes, I agree fully that another key time when to screen for financial toxicity is at that transition between treatments to best understand where they're at based off of what they've received previously for care, and then to anticipate needs when changing regimens, such as like you said in the metastatic setting. As we're collecting this information, you're right, we screen, we get this information, and what do we do? I do agree that there is a lack of knowledge among us clinicians of how do we manage this information. What is insurance? How do we manage insurance and help patients with insurance concerns? How do we help them navigate out-of-pocket costs or even the indirect costs of transportation? Those are a lot of things that are not covered in-depth in traditional medical training. And so it can be overwhelming for a lot of clinicians, not only due to time limitations in clinic, but also just having those conversations within their visit. And so what I would say, a key thing to note, is that this is another area for multidisciplinary care. So just as we're treating patients in a multidisciplinary way within oncology as we work with our medical oncology, surgical colleagues across the board, it's knowing that this is another area for multidisciplinary care. So the team members include all of the different oncologists, but it also includes team members such as financial counselors and navigators and social workers and even understanding nonprofit partners who we have who have money that can be set aside to help reduce costs for certain different aspects of treatment. Another thing I will note is that most patients with breast cancer often say they do want to have these conversations still with their clinicians. So they do still see a clinician as someone that can weigh in on the costs of their treatment or can weigh in on this other aspect of their care, even if it's not the actual medication or the radiation. And so patients do desire to hear from their clinicians about this topic, and so I think another way to make it feel less overwhelming for clinicians like ourselves is to know that even small conversations are helpful and then being knowledgeable about within your institution or, like I said, outside of it with nonprofits, being aware of who can I refer this patient to for continued follow-up and for more detailed information and resources. Dr. Hope Rugo: Are those the successful interventions? It's really referring to financial navigators? How do people identify? You know, in an academic center, we often will sort of punt this to social workers or our nurse navigators. What about in the community? What's a successful intervention example of mitigating financial toxicity? Dr. Kamaria Lee: I agree completely that the context at which people are practicing is important to note. So as you alluded to, in some bigger systems, we do have financial navigators and this has been seen to be successful in providing applications and assisting with applications for things such as pharmaceutical assistance, insurance applications, discount opportunities. Another successful intervention are financial toxicity tumor boards, which I acknowledge might not be able to exist everywhere. But where this is possible, multidisciplinary tumor boards that include both doctors and nurses and social workers and any other members of the care team have been able to effectively decrease patients' personal spending on care costs and decrease co-pays through having a dedicated time to discuss concerns as they arise or even proactively. Otherwise, I think in the community, there are other interventions in regards to understanding different aspects of government programs that might be available for patients that are not, you know, limited to an institution, but that are more nationally available, and then again, also having the nonprofit, you know, partnerships to see other resources that patients can have access to. And then I would also say that the indirect costs are a significant burden for many patients. So by that, I mean even parking costs, transportation, childcare. And so even though those aren't interventions necessarily with someone who is a financial navigator, I would recommend that even if it's a community practice, they discuss ways that they can help offset those indirect costs with patients with parking or if there are ways to help offset transportation costs or at least educate patients on other centers that may be closer to them or they can still receive wonderful care, and then also making sure that patients are able to even have appointments scheduled in ways that are easier for them financially. So even if someone's receiving care out in the community where there's not a financial navigator, as clinicians or our scheduling teams, sometimes there are options to make sure if a patient wants, visits are more so on one day than throughout the week or many hours apart that can really cause loss of income due to missed work. And so there are also kind of more nuanced interventions that can happen even without a financial navigation system in place. Dr. Hope Rugo: I think that those are really good points and it is interesting when you think about financial toxicity. I mean, we worry a lot when patients can't take the drugs because they can't afford them, but there are obviously many other non-treatment, direct treatment-related issues that come up like the parking, childcare, tolls, you know, having a working car, all those kinds of things, and the unexpected things like school is out or something like that that really play a big role where they don't have alternatives. And I think that if we think about just drug costs, I think those are a big issue in the global setting. And your article did address financial toxicity in the global setting. International financial toxicity rates range from 25% of patients with breast cancer in high-income countries to nearly 80% in low- and middle-income countries or LMICs. You had cited a recent meta-analysis of the global burnout from cancer, and that article found that over half of patients faced catastrophic health expenditures. And of course, I travel internationally and have a lot of colleagues who are working in oncology in many countries, and it is really often kind of shocking from our perspective to see what people can get coverage for and how much they have to pay out-of-pocket and how much that changes, that causes a lot of disparity in access to healthcare options, even those that improve survival. Can you comment on the global impact of this problem? Dr. Kamaria Lee: I am glad that you brought this up for discussion as well. Financial toxicity is something that is a significant global issue. As you mentioned, as high as 80% of patients with breast cancer in low- and middle-income countries have had significant financial toxicity. And it's particularly notable that even when looking at breast cancer compared to other malignancies around the world, the burden appears to be worse. This has been seen even in countries with free universal healthcare. One example is Sri Lanka, where they saw high financial toxicity for their patients with breast cancer, even with this free universal healthcare. But there were also those travel costs and just additional out-of-hospital tests that were not covered. Also, literature in low- and middle-income countries shows that patients might also be borrowing money from their social networks, so from their family and their friends, to help cover their treatment costs, and in some cases, people are making daily food compromises to help offset the cost of their care. So there is a really large burden of financial toxicity generally for cancer globally, but also specifically in breast cancer, it warrants specific discussion. In the meta-analysis that you mentioned, they identified key risk factors of financial toxicity globally that included people who had a larger family size, a lower income, a lack of insurance, longer disease duration, so again, the accumulation of visits and costs and co-pay over time, and those who had multiple treatments. And so in the global setting, there is this significant burden, but then I will also note that there is a lack of literature in low-income countries on financial toxicity. So where we suspect that there is a higher burden and where we need to better understand how it's distributed and what interventions can be applied, especially culturally specific interventions for each country and community, there's less research on this topic. So there is definitely an increased need for research in financial toxicity, particularly in the global setting. Dr. Hope Rugo: Yes, and I think that goes on to how we hope that financial toxicity researchers will have approaches to large-scale multi-institutional interventions to improve financial toxicity. I think this is an enormous challenge, but one of the SWOG organizations has done some great work in this area, and a randomized trial addressing cancer-related financial hardship through the delivery of a proactive financial navigation intervention is one area that SWOG has focused on, which I think is really interesting. Of course, that's going to be US-based, which is how we might find our best paths starting. Do you think that's a good path forward, maybe that being able to provide something like that across institutions that are independent of being a cancer only academic center, or more general academic center, or a community practice? You know, is finding ways to help patients with breast cancer and their families understand and better manage financial aspects of cancer care on a national basis the next approach? Dr. Kamaria Lee: Yes, I agree that that is a good approach, and I think the proactive component is also key. We know that patients that are coming to us with any cancer, but including breast cancer, some of them have already experienced a financial burden or have recently had a job loss before even coming to us and having the added distress of our direct costs and our indirect costs. So I think being proactive when they come to us in regards to the additional burden that their cancer treatments may cause is key to try to get ahead of things as much as we can, knowing that even before they've seen us, there might be many financial concerns that they've been navigating. I think at the national level, that allows us to try to understand things at what might be a higher level of evidence and make sure that we're able to address this for a diverse cohort of patients. I know that sometimes the enrollment can be challenging at the national level when looking at financial toxicity, as then we're involving many different types of financial navigation partners and programs, and so that can maybe make it more complex to understand the best approaches, but I think that it can be done and can really bring our understanding of important financial toxicity interventions to the next level. And then the benefit to families with the proactive component is just allowing them to feel more informed, which can help decrease anticipation, anxiety related to anticipation, and allow them to help plan things moving forward for themselves and for the whole family. Dr. Hope Rugo: Those are really good points and I wonder, I was just thinking as you were talking, that having some kind of a process where you could attach to the electronic health record, you could click on the financial toxicity survey questions that somebody filled out, and then there would be a drop-down menu for interventions or connecting you to people within your clinic or even more broadly that would be potential approaches to manage that toxicity issue so that it doesn't impact care, you know, that people aren't going to decide not to take their medication or not to come in or not to get their labs because of the cost or the transportation or the home care issues that often are a big problem, even parking, as you pointed out, at the cancer center. And actually, we had a philanthropic donor when I was at UCSF who donated a large sum of money for patient assistance, and it was interesting to then have these sequential meetings with all the stakeholders to try and decide how you would use that money. You need a big program, you need to have a way of assessing the things you can intervene with, which is really tough. In that general vein, you know, what are the governmental, institutional, and provider-level actions that are required to help clinicians do our best to do no financial harm, given the fact that we're prescribing really expensive drugs that require a lot of visits when caring for our patients with breast cancer in the curative and in the metastatic setting? Dr. Kamaria Lee: At the governmental level, there are patient assistant programs that do exist, and I think that those can continue and can become more robust. But I also think one element of those is oftentimes the programs that we have at the government level or even institutional levels might have a lot of paperwork or be harder for people with lower literacy levels to complete. And so I think the government can really try to make sure that the paperwork that is given, within reason, with all the information they need, but that the paperwork can be minimized and that there can be clear instructions, as well as increased health insurance options and, you know, medical debt forgiveness as more broad just overall interventions that are needed. I think additionally, institutions that have clinical trials can help ensure that enrollment can be at geographically diverse locations. Some trials do reimburse for travel costs, of course, but sometimes then patients need the reimbursement sooner than it comes. And so I think there's also those considerations of more so upfront funds for patients involved in clinical trials if they're going to have to travel far to be enrolled in that type of care or trying to, again, make clinical trials more available at diverse locations. I would also say that it's important that those who design clinical trials use what is known as the “Common Sense Oncology” approach of making sure that they're designed in minimizing the use of outcomes that might have a smaller clinical benefit but may have a high financial toxicity. And that also goes to what providers can do, of understanding what's most important to a particular patient in front of them, what outcomes and what benefit, or you know, how many additional months of progression-free survival or things like that might be important to a particular patient and then also educating them and discussing what the associated financial burden is just so that they have the full picture as they make an informed decision. Dr. Hope Rugo: As much as we know. I mean, I think that that's one of the big challenges is that as we prescribe these expensive drugs and often require multiple visits, even, you know, really outside of the clinical trial setting, trying to balance the benefit versus the financial toxicity can be a huge challenge. And that's a big area, I think, that we still need help with, you know. As we have more drugs approved in the early-stage setting and treatments that could be expensive, oral medications, for example, in our Medicare population where the share of cost may be substantial upfront, you know, with an upfront cost, how do we balance the benefits versus the risk? And I think you make an important point that discussing this individually with patients after we found out what the cost is. I think warning patients about the potential for large out-of-pocket cost and asking them to contact us when they know is one way around this. You know, patients feeling like they're sort of out there with a prescription, a recommendation from their doctor, they're scared of their cancer, and they have this huge share of cost that we didn't know about. That's one challenge, and I don't know if there's any suggestions you have about how one should approach that communication with the patient. Dr. Kamaria Lee: Yes, I think part of it is truly looking at each patient as an individual and asking how much they want to know, right? So we all know that patients, some who want more information, some want less, and so I think one way to approach that is asking them about how much information do they want to know, what is most helpful to them. And then also, knowing that if you're in a well-resourced setting that does have the social workers and financial navigators, also making sure it's integrated in the multidisciplinary setting and so that they know who they can go to for what, but also know that as a clinician, you're always happy for them to bring up their concerns and that if it's something that you're not aware of, that you will connect them to the correct multidisciplinary team members who can accurately provide that additional information. Dr. Hope Rugo: Do you have any other additional comments that you'd like to mention that we haven't covered? I think the idea of a financial toxicity screen with two questions that could be implemented at change of therapy or just periodically throughout the course of treatment would be a really great thing, but I think we do need as much information on potential interventions as possible because that's really what challenges people. It's like finding out information that you can't handle. Your article provides a lot of strategies there, which I think are great and can be discussed on a practice and institutional level and applied. Dr. Kamaria Lee: Yeah, I would just like to thank you for the opportunity to discuss such an important topic within oncology and specifically for our patients with breast cancer. I agree that it can feel overwhelming, both for clinicians and patients, to navigate this topic that many of us are not as familiar with, but I would just say that the area of financial toxicity is continuing to evolve as we gather more information on most successful interventions and that our patients can often inform us on, you know, what interventions are most needed as we see them. And so you can have your thinking about it as you see individual patients of, "This person mentioned this could be more useful to them." And so I think also learning from our patients in this space that can seem overwhelming and that maybe we weren't all trained on in medical school to best understand how to approach it and how to give our patients the best care, not just medically, but also financially. Dr. Hope Rugo: Thank you, Dr. Lee, for sharing your insights with us today. Our listeners will find a link, as I mentioned earlier, to the Ed Book article we discussed today in the transcript of this episode. I think it's very useful, a useful resource, and not just for providers, but for clinic staff overall. I think this can be of great value and help open the discussion as well. Dr. Kamaria Lee: Thank you so much, Dr. Rugo. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at Education Sessions from ASCO meetings and our deep dives into new approaches that are shaping modern oncology. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Hope Rugo @hope.rugo Dr. Kamaria Lee @ lee_kamaria Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Kamaria Lee: No relationships to disclose
In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über das Wettrennen um die Fed-Spitze, einen ungewohnten Rheinmetall-Rücksetzer und starke Siemens-Zahlen. Außerdem geht es um Intel, Amgen, Merck, Abbvie, Pfizer, Eli Lilly, Novo Nordisk, Pinterest, Rheinmetall, Deutsche Telekom, Siemens, Allianz, Ionos, Microsoft, Alphabet, Softbank und AirBnB. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today. Just to note, our full disclosures are available in the transcript of this episode. Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind. Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the ‘sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very important that these young patients do receive counseling about fertility preservation prior to starting treatment. Dr. Sumanta (Monty) Pal: You know, it's so interesting you bring this up, and I think about a patient who's in their 40s diagnosed with this disease. They're in the same demographic as I am, as you are. You know, I'm 44 years old, and you know, I'm thinking about my 11- and 12-year-old and my aging parents, right? I mean, the dilemmas that you highlighted are precisely what I'm facing in life, and it's so true, right? If I had to take my day-to-day and superimpose on that a colorectal cancer diagnosis, it would just be problematic in so many spheres, so many spheres. Dr. Kimmie Ng: Absolutely. And because we did think going into this, starting our Young-Onset Colorectal Cancer Center, that these patients will need unique supports, we did conduct a qualitative study and held some focus groups of young-onset colorectal cancer patients as well as their caregivers. And we really identified four primary themes that I think reflect a lot of the experience of patients with cancer, no matter what type of cancer when they're diagnosed young. And the first is the need, feeling overwhelmed by the healthcare system, and the need for patient navigation. As we know, a lot of these patients are previously healthy before they're facing this very serious diagnosis. The second is the need for peer-to-peer support, where they really value connecting with other young patients going through a similar experience. The third, we talked about already, the need for kind of formal psychosocial support in the form of psychosocial oncologists or psychiatrists or social workers. And the last is an interest in research. They are really very invested in getting germline genetic testing as well as somatic genomic profiling to help guide their therapy. Dr. Sumanta (Monty) Pal: That's really encouraging to hear that they themselves are interested in participating in research. I mean, obviously, that's a great way to move the field forward. I view your area of work here as being such a vexing problem because no matter what way you slice it, young-onset colorectal cancer still remains a relatively small proportion of all diagnoses. So how do you go about studying this phenomenon? I mean, it must be challenging to really sort of investigate underlying causes when ostensibly this is still a small piece of the pie. Dr. Kimmie Ng: That is such a great question and is one of the challenges me and my research team think about every single day. As you mentioned, one of the major barriers is that although these cancers are rising in young people, the absolute number of patients being diagnosed is still relatively small, and if it's going to take large scale epidemiologic studies to really understand, for example, what the dietary and lifestyle risk factors are, you need a considerable number of patients in order to have enough power to reach definitive conclusions. And so this is where it is so important to collaborate. Any single institution is not going to see enough young-onset patients with colorectal cancer to be able to do this work on their own. And so I have really been intent on establishing an international prospective cohort study of patients with young-onset colorectal cancer so that we can increase the numbers of patients we partner with to try to answer these questions, but also so that we can study this on a global scale, because unfortunately this is not something that's just plaguing the United States. It is actually happening in multiple countries around the world. So that is one barrier. The second, I would say, is that we think it's early life exposures to whatever environmental factor it is that's causing the rise that is likely contributing the most. And so if you imagine how difficult it would be to start studying individuals from when they're children through adolescence, through adulthood, and then all the way until a cancer diagnosis is obtained, a study like that would take too long, would cost too much, and really wouldn't be feasible. So we need to think of alternative ways to really try and answer this question of what is driving this rise in young-onset colorectal cancer. Dr. Sumanta (Monty) Pal: Honestly, Kimmie, this seems like almost an unfair question in the context of what you just mentioned, the challenges in terms of ascertaining causality, right? I'll tell you, I cheated a little bit ahead of this podcast. Kimmie and I had dinner together in Los Angeles a couple months ago. She came out to deliver a Presidential Lectureship at City of Hope. We were delighted to have her. And we did have a couple of thoughts exchanged over potential drivers of these early diagnoses, leaning on perhaps one of the things that you and I are both interested in, the microbiome. But amongst all these things, vitamin D, microbiome, etc., and I won't hold you to this, do you have at least a general sense of what might be contributing to this early-onset phenomenon? Dr. Kimmie Ng: Yeah, as we talked about during my visit there to City of Hope, we do hypothesize that it is a complex interaction between our exposome, which is everything we are exposed to in our environment, which does include diet and lifestyle factors, interacting with host immunity and antitumor immunity, and as well as the microbiome and shaping the composition and diversity of the gut microbiome that are likely interacting to increase susceptibility to colorectal cancer at a younger age. And I will say one of the biggest discoveries, if you will, about what might be driving young-onset colorectal cancer was published a few months ago in Nature. And that paper identified a specific mutational signature caused by the genotoxin colibactin, which is often produced by an organism called pks+ E. coli, as being much more prevalent in younger patients with colorectal cancer than older patients. And so while it doesn't explain necessarily all of young-onset colorectal cancer and why it's rising, it does give us a clue that the microbiome is likely very important in perhaps why this is rising in young people. Dr. Sumanta (Monty) Pal: After you mentioned it, I went back and dove deep into that paper. I was fascinated, fascinated by the content there. And this is just a massive exploration across thousands of patients worldwide. So, I mean, if there is a way to get at least some hint of what's driving this phenomenon, I suppose that's it. So thank you for pointing me in the direction of that manuscript. Now that we've addressed the issue of diagnosis, if we could just, you know, verge on the topic of treatment, right? And this is something that I struggle with. When I have my young patients with kidney cancer, I don't know necessarily that my treatment paradigm changes a whole heck of a lot. I guess what I will say is I might be a little bit more aggressive about concepts like definitive management with surgery. I suppose perhaps their treatment tolerance is a little bit higher. But tell us about the setting of young-onset colorectal cancer. Is the philosophy any different in terms of the actual sort of management of these patients? Dr. Kimmie Ng: That's a great question, and actually I was honored to participate in the first international consensus guidelines group to try to come up with uniform recommendations for how to treat young patients with colorectal cancer. And you know, the overall consensus is just as you said, the medical care of these young patients right now is really not that much different than that of an older patient with colorectal cancer. There are a couple of distinctions. One is that all young patients should get germline genetic testing, given that there is a higher prevalence of pathogenic germline variants when you are diagnosed at a young age. And the second is what we've already talked about, which is that all young patients should be referred for counseling about fertility preservation prior to starting treatment. But otherwise, the chemotherapy regimens recommended, you know, surgery, radiation, all of that seems very similar to older patients. I will say that because most of our young patients with colorectal cancer are diagnosed with left-sided cancers, including rectal cancers, where some of the treatment may be morbid and result in lifelong complications, we do consider de-escalation of therapy and try to consider the long-term implications when it's safe to do so and won't compromise outcomes. The other concerning thing is that younger patients don't necessarily have a better prognosis than older patients. And multiple studies have shown this, that even though we both often treat younger patients more aggressively – they more often receive multi-agent chemotherapy, and more often undergo surgery and radiation – their survival is not necessarily correspondingly better than an older patient with colorectal cancer. So that suggests to us that maybe these cancers are indeed biologically different and perhaps more aggressive or perhaps less responsive to treatment. And so that is some of the focus of our research too, to understand what is actually different about these cancers and how they respond to treatment. Dr. Sumanta (Monty) Pal: It's such a paradox, isn't it, right? Because you just brought this to my mind. I guess on the one hand, our younger patients may be able to tolerate perhaps a greater amount of chemotherapy, targeted therapy, etc. But you're absolutely right. I mean, they do sort of have these lingering issues with side effects that may persist for much longer than the 80- or 90-year-old that we're treating in the clinic. I mean, these tend to be sort of lifelong consequences and sequelae that they're dealing with. So that really does evolve to be a challenge. You've kind of changed my mindset there a little bit. Dr. Kimmie Ng: Yeah, I do think survivorship issues and long-term complications of therapy do need to be considered, especially for a young person who we hope will live a very, very long time. And so part of the work that our Young-Onset Colorectal Cancer Center is doing, we are participating in a pilot navigation study where we navigate patients to survivorship earlier than we typically would, perhaps, for an older patient. And that's so we can get a head start on addressing some of those potential complications of therapy and hopefully mitigate them so that they don't become an issue long term. Dr. Sumanta (Monty) Pal: Do you think there's a role for de-escalation studies formally in these young populations of patients? Dr. Kimmie Ng: I think de-escalation studies are important overall, and specifically for locally advanced rectal cancer, which again is one of the most common types of colorectal cancer diagnosed in our young patients, there are certain populations that may be able to forgo the radiation treatment to the pelvis, for example, and there's more and more patients who now may become candidates for non-operative management where they may not necessarily need to have their rectal cancer surgically removed. And elimination potentially of both of those modalities of treatment can really avoid some of the most serious and morbid complications that often occur with these treatments. Dr. Sumanta (Monty) Pal: Really interesting. Now, this is not and will never be a political podcast, but you know, obviously we're dealing with the consequences of changes on funding and so forth that have evolved over time. And I think it's worth sort of speculating how the landscape of research may change on account of that. Could you comment perhaps a little bit on how some of the funding cuts that we've seen recently at the NIH might affect the body of work that you're so integrally involved in? Dr. Kimmie Ng: I am honestly very worried about the current funding environment. Colorectal cancer is the third most commonly diagnosed cancer among men and women in the United States and globally, and when you combine men and women together, the second leading cause of cancer death. But proportionally, we receive much less funding for colorectal cancer compared to other cancer types. And my thoughts have always been that perhaps this is because there is this stigma around colorectal cancer and maybe some of the symptoms associated with colorectal cancer. And so on top of that, to have additional challenges in obtaining funding, I worry what it will do to the pace of progress for especially young patients with this disease. Also, because of some new stipulations that perhaps international collaborations are being discouraged, I also worry about that aspect of it because young-onset colorectal cancer and gastrointestinal cancers in general is a global phenomenon happening in multiple countries around the world. And if we are to understand what the environmental factors are affecting the different rates of rise in these different countries, we do so much need that international collaboration. So yes, I am worried, and I do hope that conversations like this will spark an awareness of the need for more funding and continued funding into this disease. Dr. Sumanta (Monty) Pal: I will say that, and the audience can't see this because this is an audio program, but I'm wearing my Southwest Oncology shirt here, a SWOG, and it's one of the National Cancer Institute-funded cooperative groups. And you know, I was recently dismayed to find that, you know, funding got cut for international collaborations and enrollment in South America and Latin America. And this was traditionally actually a mainstay of our enrollment for many trials, including trials in rare cancers that present themselves in younger patients in the GU space. So, I completely agree with you. We've got to do something to address this funding issue to make sure that this body of work, both yours and mine, continues, without a doubt. Kimmie, this has been a delightful conversation. I really want to thank you for, you know, leading the charge in the young-onset colorectal cancer space, and you've done so much tremendous work here. Dr. Kimmie Ng: Thank you for having me. Dr. Sumanta (Monty) Pal: If you value the insights that you hear on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. And again, thank you for joining us today. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Sumanta (Monty) Pal @montypal Dr. Kimmie Ng @KimmieNgMD Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Kimmie Ng: Honoraria: Seagen, GlaxoSmithKline Consulting or Advisory Role: CytomX Therapeutics, Jazz Pharmaceuticals, Revolution Medicines, Abbvie, Bayer, Pfizer, Agenus, Johnson & Johnson/Janssen, Etiome, AstraZeneca Research Funding (Inst.): Pharmavite, Janssen Other Relationship: JAMA
US President Trump said they are going to be putting a very large tariff on chips and semiconductors, which will be at approximately 100%, but added "if you're building in the US, there will be no charge."Crude futures declined yesterday amid Russia/Ukraine optimism following the discussion between the US and Russia which was said to have made progress and with President Trump intending to meet Russian President Putin as soon as next week.US President Trump said, regarding the Fed pick, that the interview process has started and it is probably down to three candidates, while he added that the two Kevins are very good, and a temporary governor is to be named in the next few days.APAC stocks traded mixed as reciprocal tariffs took effect overnight; European equity futures indicate a marginally higher cash market open with Euro Stoxx 50 futures up 0.4% after the cash market closed with gains of 0.3% on Wednesday.Looking ahead, highlights include German Trade (Jun), Industrial Output (Jun), Swedish CPIF (Jul), French Trade Balance (Jun), US Jobless Claims, Wholesale Sales (Jun) NY Fed SCE, Atalanta Fed GDP, BoE Announcement, MPR & DMP, CNB & Banxico Announcements, Speakers including BoE's Bailey & Fed's Bostic, Supply from Spain, France & US.Earnings from Trade Desk, Eli Lilly, ConocoPhillips, Vistra Energy, Peloton, Warner Bros, DataDog, Kenvue, Siemens, Deutsche Telekom, Allianz, Merck, Henkel, Rheinmetall, Deliveroo, Serco, Maersk, Zurich Insurance & WPP.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
Dr. Adam Kinnaird of the University of Alberta joins Dr. Aly-Khan Lalani and Dr. Christopher Wallis to explore the evolution of prostate cancer diagnostics, from the limitations of transrectal ultrasound to the rise of MRI and micro-ultrasound. They unpack key trials, discuss real-world challenges like long MRI wait times in Canada, and examine how micro-ultrasound offers a scalable, point-of-care solution. This can't-miss episode charts a path toward faster and more accurate prostate cancer care.This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca
A CVC masterclass from Bill Taranto, Founder and President of Merck's Global Health Innovation Fund, a $600M fund that is considered one of the most impactful corporate venture funds in the world. Bill has over 20 years of healthcare investing and is focused on digital health companies transforming the future of care. Bill was just named to the Global Corporate Venturing Power List for the 14th time. We talk about the dual mandate to predict and prepare as well as the unique structure he has created which includes multiple levers like accelerators, studios, the growth equity fund, and a private equity roll-up function. We talk about the right relationship with the corporate parent, flying too close to the sun in the strategic/financial balance and why communication is often what determines success and makes innovation tangible for large organizations.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Breaking News: Pfizer announces successful COVID-19 vaccine trialsIn a groundbreaking announcement, Pfizer revealed that their COVID-19 vaccine candidate has shown to be over 90% effective in preventing the virus. This news brings hope to the world as we continue to battle the global pandemic.##FDA approves new treatment for Alzheimer's diseaseThe FDA has approved a new treatment for Alzheimer's disease, marking a significant advancement in the fight against this debilitating condition. This approval could potentially change the lives of millions of patients and their families.##Johnson & Johnson recalls baby powder due to asbestos contaminationJohnson & Johnson has issued a voluntary recall of its baby powder products after trace amounts of asbestos were found in samples. This news has raised concerns about the safety of talc-based products and the potential risks they pose to consumers.##Novartis announces major breakthrough in cancer researchNovartis has made a significant breakthrough in cancer research with the development of a new targeted therapy that has shown promising results in clinical trials. This innovation has the potential to revolutionize cancer treatment and improve outcomes for patients.##Merck receives FDA approval for new diabetes drugMerck has received FDA approval for a new diabetes drug that offers another option for patients struggling to manage their condition. This approval expands treatment options and provides hope for those living with diabetes.##Roche acquires biotech company in multi-billion dollar dealRoche has announced the acquisition of a biotech company in a multi-billion dollar deal that will expand its portfolio and strengthen its position in the market. This strategic move demonstrates Roche's commitment to innovation and growth in the biotech sector.##Incyte collaborates with academic research center to develop new therapiesIncyte has formed a collaboration with an academic research center to develop new therapies for a range of diseases, including cancer and inflammatory conditions. This partnership brings together expertise from both sectors to accelerate the discovery and development of innovative treatments.##Overall, these recent developments in the pharmaceutical and biotech industry highlight the ongoing efforts to advance healthcare and improve patient outcomes. From groundbreaking vaccines to innovative therapies, these advancements are shaping the future of medicine and providing hope for patients worldwide.
Center for Drug Evaluation and Research Head George Tidmarsh will oversee the Center for Biologics Evaluation and Research on an acting basis after Vinay Prasad's abrupt departure hours after the recording of last week's episode of The Weekly. While the situation is being billed as temporary, rumors are swirling that structural changes may be afoot at the FDA with Commissioner Marty Makary looking for better drug, biologic alignment.Meanwhile, the agency has come under criticism for another recent decision—one apparently driven by CDER's Oncology Center of Excellence director Richard Pazdur: the rejection of Replimmune's advanced melanoma drug, RP1. According to reporting by multiple outlets, Pazdur opposed the consensus opinion of CBER staff to approve the drug. The research team behind Replimmune's Phase III study penned an open letter to the FDA on Friday responding to the issues outlined in the agency's complete response letter. Meanwhile, the FDA's Sarepta saga continues, highlighting “unprecedented” FDA leaks and a veritable communications disaster.On the business side of biopharma, Q2 earnings continue to unfurl, with Pfizer, Vertex, BioNTech, Merck and Moderna all reporting this past week. Merck's $3 billion savings push has claimed 6,000 jobs, contributing to a brutal July that saw the entire biopharma industry axe 7,900 employees, a 487% year-over-year increase, based on BioSpace tallies. Meanwhile, Pfizer CEO Albert Bourla confirmed he has been in direct contact with President Donald Trump to negotiate a path forward on Most Favored Nation drug pricing after the president sent letters to 17 Big Pharma companies—and posted on his Truth Social platform—asking them to comply with the policy within 60 days or face potential unspecified consequences.In other policy news, the Centers for Medicare and Medicaid Services is reportedly considering coverage of GLP-1 drugs for weight management and obesity—reviving a Biden era proposal the Trump admin scrapped earlier this year.Finally, in BioPharm Executive this week, we have a special report on the situation in China as international drugmakers swoop into the region to find new drug candidates, while other companies build their therapeutic farm systems from incubators and venture arms. And check out BioSpace's brand new Manufacturing Brief, where we bring you the latest news and analysis in the area of biopharma manufacturing, starting with a feature on how to make cell and gene therapies commercially viable.
In this episode, Mark Ledlow and Benjamin Whitfield, a seasoned security professional with a military and agency background and a former CIA, delve into the journeys of various figures transitioning from government roles to entrepreneurship, particularly focusing on Mike and Chris's post-CIA careers in the security industry and bourbon production. The conversation touches on the unique skill sets developed within the CIA, the importance of trust and networking among former agents, and the experiences that shaped their professional lives. Benjamin also shares personal anecdotes from his time with the CIA, including his harrowing experience during the terrorist attack on the American Consulate in Jetta, Saudi Arabia. The discussion provides insights into the evolving business and cultural landscape in the Middle East and how these changes impact personal and professional security.Learn about all this and more in this episode of The Fearless Mindset Podcast.KEY TAKEAWAYSReinvention is possible at any stage—skills from one career can fuel success in another. Trust and relationships are central in security and intelligence work. Bureaucratic responses can drive talented people to seek impact elsewhere. Cultural adaptation and respect are vital for success in international business. Generational shifts are changing norms in places like Saudi Arabia.QUOTES“Trust is super important in that space.” “I really have found this home in the private sector for 20 plus years now, where I can protect our people, our facilities, our operations in that appropriate way.” “It's all heavily relationship based.” “Reinvention is a skillset that both he and Chris and others have developed over a long career.”Get to know more about Benjamin Whitfield through the links below.https://www.linkedin.com/in/benjaminwhitfield/To hear more episodes of The Fearless Mindset podcast, you can go to https://the-fearless-mindset.simplecast.com/ or listen to major podcasting platforms such as Apple, Google Podcasts, Spotify, etc. You can also subscribe to the Fearless Mindset YouTube Channel to watch episodes on video.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. BioNTech is focusing on infectious diseases as vaccine rates drop, with expectations that the US COVID-19 vaccination rate will decrease slightly. Glioblastoma research is seeing increased funding and interest from companies like Merck and Jazz Pharmaceuticals. The FDA's rejection of Replimmune's melanoma drug, despite staff consensus, has caused a drop in the company's stock. Sarepta and Capricor learned of regulatory decisions through media leaks, causing confusion for patients and families. Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Lotte Biologics is expanding globally, Allogene is discontinuing an immunosuppressive antibody after a patient death, and NIH funding cuts are impacting biotech. Pharmas are increasing investment in AI despite challenges in the industry. Trump urges pharma companies to address drug pricing, while Merck plans to cut 6,000 jobs to save $3 billion.
Audio roundup of selected biopharma industry content from Scrip over the business week ended August 1, 2025. In this episode: EU tariff deal leaves questions for pharma; Prasad's CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AOJAANRHLNCPNNLNGVVKA3HEAE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Moderna CEO Stephane Bancel has stated that the company is not interested in pursuing mergers and acquisitions, preferring to focus on research and development partnerships instead. Former President Trump has threatened 17 big pharmaceutical companies with a deadline to lower drug prices or face government intervention. Regeneron faces regulatory issues affecting decision dates for high-dose Eylea, while Moderna has won a UK patent battle against Pfizer and BioNTech. After the removal of FDA chief Dr. Prasad, Dr. Makary is seeking better alignment between drug and biologic approvals at the agency. Alnylam's impressive sales of Amvuttra ATTR-CM have led to a surge in stock prices, while Merck is aiming to save $3 billion through job cuts. Moderna is also cutting 10% of its global workforce. Recent FDA approvals for myeloma and Alzheimer's treatments, as well as updates on layoffs and pipeline developments in the biotech industry are also making headlines.
https://engagedly.com/podcast/rebuilding-trust-in-equity-and-inclusion-with-celeste-warren-episode-84/Celeste Warren is a globally recognized DEI strategist, author, and former Vice President and Chief Diversity and Inclusion Officer at Merck. With nearly 40 years of experience in global HR, Celeste is a leading voice on how equity transforms organizations from the inside out. Her journey began as a journalist uncovering pay inequities—and evolved into a powerful career in DEI leadership, helping companies dismantle systemic barriers and build more inclusive cultures. She is the author of The Truth About Equity: What It Really Is, What It Isn't, and Why Everyone Wins When We Get It Right, a book that challenges misunderstandings about equity and offers a path forward for individuals and organizations alike.Learn more at https://www.crwdiversity.comEpisode Overview:This episode explores the real meaning of equity in the workplace and why it's essential for both organizational performance and human dignity. Celeste Warren joins host Sri Chellappa to discuss the DEI backlash, the misconceptions surrounding equity, and what leaders must do to build truly inclusive and high-performing teams.Key Discussion Points:Guest Introduction and Career Journey: Celeste shares her background—from discovering pay disparities in journalism to becoming a global DEI leader. Her passion for driving equity across all dimensions of identity sets the foundation for the conversation.What Equity Really Means: Celeste explains the key differences between equity and equality, arguing that equity isn't about giving some people more—it's about giving everyone what they need to succeed.Why DEI Is Facing Backlash: She unpacks the political and societal pushback against DEI, emphasizing that much of it stems from misunderstanding or resistance to systemic change.The “Three-Rock” Analogy: Using a visual metaphor, Celeste describes how equity programs help level the playing field for everyone—and why those who've always had privilege often fail to see the barriers others face.DEI as Business and Leadership Strategy: Celeste reframes DEI not as a “nice to have,” but as fundamental to leadership, talent development, and customer understanding. She connects equity to performance, innovation, and long-term sustainability.Global Equity Challenges: Reflecting on her work at Merck and Kraft Foods, Celeste shares how she tailored DEI strategies for global audiences while respecting local cultural nuances.A Call to Action for Today's Leaders: Celeste urges leaders to meet people where they are, embrace inclusive practices, and recognize equity as essential to unlocking collective success.
Belén Garijo führt eines der ältesten Pharmaunternehmen Deutschlands und treibt den Wandel zum Technologiekonzern voran. Ein Gespräch über Innovation, Leadership und ihren Weg von einem Krankenhaus in Madrid an die Spitze eines Dax-Konzerns.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.
The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug. Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week. Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.” On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year. In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike. And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.
What do F1-linked scandals, Ponzi schemes, and popcorn-serving robot dogs have in common? Hosted by Michelle Martin with Ryan Huang, today’s Market View dives into Hotel Properties Limited (HPL) and its Orchard Road asset play, and the fallout from Envy Asset Management’s billion-dollar nickel scam. We also unpack shifting US trade policy under President Trump and its implications for Singapore, with the 10% tariff still looming. In our corporate roundup, we dissect the latest from AstraZeneca, Merck, Novo Nordisk, UOB’s United Overseas Insurance, and First REIT. Finally, we marvel at Unitree, UBTech Robotics, and Agibot at China’s AI Summit. From legal woes to leaping robot dogs—don’t miss today’s episode.See omnystudio.com/listener for privacy information.
“Manager and leader”? What's the difference. During my conversation this time with Scott Hanton, our guest, we will discuss this very point along with many other fascinating and interesting subjects. As Scott tells us at the beginning of this episode he grew up asking “why” about most anything you can think of. He always was a “why” asker. As he tells it, unlike many children who grow out of the phase of asking “why” he did not. He still asks “why” to this very day. At the age of 13 Scott decided that he wanted to be a chemist. He tells us how this decision came about and why he has always stayed with it. Scott received his bachelor's degree in Chemistry from Michigan State and his PHD from the University of Wisconsin. Again, why he changed schools for his PHD work is an interesting story. As you will see, Scott tells stories in a unique and quite articulate way. After his university days were over Scott went to work, yes as a chemist. He tells us about this and how after 20 years with one company how and why he moved to another company and somewhat out of constant lab work into some of the management, business and leadership side of a second company. He stayed there for ten years and was laid off during the pandemic. Scott then found employment as the editorial director of Lab Management Magazine where he got to bring his love of teaching to the forefront of his work. My hour with Scott gives us all many insights into management, leadership and how to combine the two to create a strong teaming environment. I believe you will find Scott's thoughts extremely poignant and helpful in everything that you do. About the Guest: Scott Hanton is the Editorial Director of Lab Manager. He spent 30 years as a research chemist, lab manager, and business leader at Air Products and Intertek. Scott thrives on the challenges of problem-solving. He enjoys research, investigation, and collaboration. Scott is a people-centric, servant leader. He is motivated by developing environments where people can grow and succeed, and crafting roles for people that take advantage of their strengths. Scott earned a BS in chemistry from Michigan State University and a PhD in physical chemistry from the University of Wisconsin-Madison. He is an active member of the American Chemical Society (ACS), the American Society of Mass Spectrometry (ASMS), and the Association of Lab Managers (ALMA). As a scientist Scott values curiosity, innovation, progress, and delivery of results. Scott has always been motivated by questions beginning with why. Studying physical chemistry in graduate school offered the opportunity to hone answers to these questions. As a professional scientist, Scott worked in analytical chemistry specializing in MALDI mass spectrometry and polymer characterization. At Scott married his high school sweetheart, and they have one son. Scott is motivated by excellence, happiness, and kindness. He most enjoys helping people and solving problems. Away from work, Scott enjoys working outside in the yard, playing strategy games, and participating in different discussion groups. Scott values having a growth mindset and is a life-long learner. He strives to learn something new everyday and from everyone. One of the great parts of being a trained research scientist is that failure really isn't part of his vocabulary. He experiments and either experiences success or learns something new. He values both individual and organizational learning. Scott's current role at Lab Manager encompasses three major responsibilities: · Writing articles and giving presentations to share his experience with lab managers. · Driving the creation and growth of the Lab Manager Academy (https://labmanageracademy.com/) that currently contains three certificate programs: lab management, lab safety management, and lab quality management. · Helping people through his knowledge of science, scientists, management, and leadership. He is very happy sharing the accumulated wisdom of his experiences as a researcher, lab supervisor, and lab manager. Each article posted on Lab Manager addresses a decision that a lab manager needs to make. Lab management is full of decision-making, so helping people make better, faster, more complete decisions is very satisfying. Ways to connect with Scott: https://www.linkedin.com/in/scott-hanton/ About the Host: Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog. Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards. https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/ accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/ https://www.facebook.com/accessibe/ Thanks for listening! Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below! Subscribe to the podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset . Leave us an Apple Podcasts review Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts. Transcription Notes: Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us. Michael Hingson ** 01:20 Well, welcome to another episode of unstoppable mindset where inclusion diversity and the unexpected meet, and mostly we get to deal with the unexpected, as opposed to inclusion or diversity. But that's okay, because unexpected is what makes life fun, and our guest today, Scott Hanton, will definitely be able to talk about that. Scott has been a research chemist. He comes from the chemistry world, so he and I in the past have compared notes, because, of course, I come from the physics world, and I love to tell people that the most important thing I learned about physics was that, unlike Doc Brown, although I do know how to build a bomb, unlike Doc Brown from Back to the Future, I'm not dumb enough to try to go steal fissionable material from a terrorist group to build the bomb. So, you know, I suppose that's a value, value lesson somewhere. But anyway, I am really glad that you're all here with us today, and we have lots to talk about. Scott, as I said, was in chemistry and research chemist, and now is the editorial supervisor and other things for a magazine called lab manager, and we will talk about that as well. So Scott, welcome to unstoppable mindset. We're glad Scott Hanton ** 02:38 you're here. Thank you for having me. I'm excited to have this conversation with you today. Michael Hingson ** 02:43 Well, I think it'll be a lot of fun, and looking forward to it. Now, you're in Michigan, right? Scott Hanton ** 02:48 That's right. I live in South Lyon, Michigan, Michael Hingson ** 02:51 ah, what's the weather back there today? Scott Hanton ** 02:55 It's probably about 55 degrees and cloudy Michael Hingson ** 02:58 here today. Well, it's still fairly sunny here, and we're actually, according to my iPhone, at 71 so it was up around 80 earlier in the week, but weather changes are still going to bring some cold for a while Scott Hanton ** 03:15 in here in Michigan, I visited a customer earlier this week, and I drove by about 1000 orange barrels on the highway, which means it's spring, because there's only two seasons in Michigan, winter and construction. Michael Hingson ** 03:29 There you go. Yeah, I know. I went to the University of California, Irvine, UCI. And if you ask somebody who doesn't know that UCI stands for University of California at Irvine. If you ask them what UCI stands for, they'll tell you, under construction indefinitely. Sounds right? Yeah. Well, it's been doing it ever since I was there a long time ago, and they they continue to grow. Now we're up to like 32,000 fresh, or excuse me, undergraduates at the university. And when I was there, there were 2700 students. So it's grown a little. That's Scott Hanton ** 04:05 a lot of change. I'm used to big universities. I'm a graduate of both Michigan State and the University of Wisconsin. So these are big places. Michael Hingson ** 04:13 Wow, yeah. So you're used to it. I really enjoyed it when it was a small campus. I'm glad I went there, and that was one of the reasons that caused me to go there, was because I knew I could probably get a little bit more visibility with instructors, and that would be helpful for me to get information when they didn't describe things well in class. And it generally worked out pretty well. So I can't complain a lot. Perfect. Glad it worked well for you, it did. Well, why don't you start, if you would, by telling us kind of about the early Scott growing up and all that sort of stuff. Scott Hanton ** 04:49 I grew up in Michigan, in a town called Saginaw. I was blessed with a family that loved me and that, you know, I was raised in a very. Supportive environment. But young Scott asked, Why about everything you know, the way kids do? Yeah, right. And my mom would tell you that when I was a kid, why was my most favorite word? And most kids outgrow that. I never did, yeah, so Me neither. I still ask why all the time. It's still my most favorite word, and it caused me to want to go explore the sciences, because what I found, as I learned about science, was that I could get answers to why questions better in science than in other places. Michael Hingson ** 05:34 Yeah, makes sense. So what kinds of questions did you ask about why? Well, I asked Scott Hanton ** 05:43 all kinds of questions about why, like, why are we having that for dinner? Or, why is my bedtime so early? Those questions didn't have good answers, at least from my perspective, right? But I also asked questions like, why is grass green, and why is the sky blue? And studying physical chemistry at Michigan State answered those questions. And so Michael Hingson ** 06:03 how early did you learn about Rayleigh scattering? But that's you know? Scott Hanton ** 06:07 Well, I learned the basic concepts from a really important teacher in my life, Mr. Leeson was my seventh grade science teacher, and what I learned from him is that I could ask questions that weren't pertinent to what he was lecturing about, and that taught me a lot about the fact that science was a lot bigger than what we got in the curriculum or in the classroom. And so Mr. Leeson was a really important person in my development, and showed me that there was that science was a lot bigger than I thought it was as a student, but I didn't really learn about rally scattering until I got to college. Michael Hingson ** 06:43 But at the same time, it sounds like he was willing to allow you to grow and and learn, which so many people aren't willing to do. They're too impatient. Scott Hanton ** 06:58 He was a first year teacher the year I had him so he hadn't become cynical yet. So it was great to just be able to stay after class and ask him a question, or put my hand up in class and ask him a question. He also did a whole series of demonstrations that were fabulous and made the science come to life in a way that reading about it doesn't stir the imagination. Yeah, Michael Hingson ** 07:23 I had teachers that did that too. I remember very well my freshman general science teacher in high school, Mr. Dills, and one day, and he loved to do kind of unique things, just to push the boundaries of students a little bit. He came in one day and he said, I got a pop quiz for everybody, which doesn't help me, because the pop quiz was in print, but he handed it out. And then he took me to the back of the room, and he said, You're not going to really be able to do this quiz. Let me tell you why. And he said, Oh, and one thing he said is, just be sure you follow all the instructions and you'll be fine on the test to everybody. He brought me back to the back of the room. He says, Well, here's the deal. He says, if people really read the instructions, what they'll do is they'll read the instruction that says, Read all the questions before you start answering, and if you get to the last question, it says answer only the first question, which is what is your name and and sure enough, of course, people didn't read the instructions. And he said, so I wouldn't be able to really deal with you with that one, with that whole thing, just because it wouldn't work well. And I said, I understand, but he loved to make students think, and I learned so much about the whole concept of realizing the need to observe and be observant in all that you do. And it was lessons like that from him that really helped a lot with that. For me, Scott Hanton ** 08:48 I had a high school chemistry teacher named Mrs. Schultz, and the first experiment that we did in her class, in the first week of classes, was she wanted us to document all of the observations that we could make about a burning candle. And I was a hot shot student. Thought I, you know, owned the world, and I was going to ace this test. And, you know, I had maybe a dozen observations about a burning candle, and thought I had done a great job describing it, until she started sharing her list, and she probably had 80 observations about a burning candle, and it taught me the power of observation and the need to talk about the details of those observations and to be specific about what the observations were. And that experiment seems simple, light a candle and tell me what you see. Yeah, but that lesson has carried on with me now for more than approaching 50 years. Michael Hingson ** 09:47 Let's see, as I recall, if you light a candle, what the center of the flame is actually pretty cool compared to the outside. It's more hollow. Now I wouldn't be able to easily tell that, because. Is my my process for observing doesn't really use eyesight to do that, so I I'm sure there are other technologies today that I could use to get more of that information. But Scott Hanton ** 10:12 I'm also sure that that experiment could be re crafted so that it wasn't so visual, yeah, right, that there could be tactile experiments to tell me about observations or or audible experiments about observation, where you would excel in ways that I would suffer because I'm so visually dominant. The Michael Hingson ** 10:33 issue, though, is that today, there's a lot more technology to do that than there was when I was in school and you were in school, but yeah, I think there is a lot available. There's a company called Independence Science, which is actually owned and run by Dr Cary sapollo. And Carrie is blind, and he is a blind chemist, and he wanted to help develop products for blind people to be able to deal with laboratory work. So he actually worked with a company that was, well, it's now Vernier education systems. They make a product called LabQuest with something like 80 different kinds of probes that you can attach to it, and the LabQuest will will provide visual interpretations of whatever the probes are showing carry, and independent science took that product and made it talk, so that There is now a Talking LabQuest. And the reality is that all those probes became usable because the LabQuest became accessible to be able to do that, and they put a lot of other things into it too. So it's more than just as a talking device, a lab device. It's got a periodic table in it. It's got a lot of other kinds of things that they just put in it as well. But it's really pretty cool because it now makes science a whole lot more accessible. I'm going to have to think about the different kinds of probes and how one could use that to look at a candle. I think that'd be kind of fun. Scott Hanton ** 12:15 And it's just awesome to hear that there's innovation and space to make science more available to everybody. Yeah, Michael Hingson ** 12:23 the real problem that we face is the one that we mostly always have faced, which is societal attitudes, as opposed to really being or not being able to do the experiments, is people think we can't, and that's the barrier that we always, usually have to overcome. Scott Hanton ** 12:39 What I find in my time as a coach, mentor, supervisor, is that if somebody believes they can't do it, they can't do it. Yeah. And so it's often about overcoming their own mental limitations, the limitations that they've placed on themselves, Michael Hingson ** 12:56 and that's right, or unfortunately, the limitations that other people place on us, and we, all too often and weigh too much, buy into those limitations. So it's it is something that we, especially in the sciences, should recognize that we shouldn't be doing so much of. I know that when I was at UC Irvine as a graduate student, I learned once that there was a letter in my file that a professor wrote. Fortunately, I never had him as a professor, but it and I was in my master's program at the time in physics, and this guy put a letter in my file saying that no blind person could ever absorb the material to get an advanced degree in physics at the University. Just put that in there, which is so unfortunate, because the real thing that is demonstrated there is a prejudice that no scientist should ever have. Scott Hanton ** 13:51 I'm hopeful that as you graduated, there was a retraction letter in your file as well, Michael Hingson ** 13:57 not that I ever heard, but yeah. Well, I'd already gotten my bachelor's degree, but yeah. But you know, things happen, but it is a it is a societal thing, and society all too often creates limitations, and sometimes we don't find them right away, but it is one of the big issues that, in general, we have to deal with. And on all too often, society does some pretty strange things because it doesn't understand what science is all about. I know when we were dealing with covid, when it all started, leaving the conspiracy theorists out of it. One of the things that I learned was that we have all these discussions about AI, if you will. But AI was one of the primary mechanisms that helped to develop the mRNA vaccines that are now still the primary things that we use to get vaccinated against covid, because they the artificial intelligence. I'm not sure how artificial. It is, but was able to craft what became the vaccine in a few days. And scientists acknowledged, if they had to do it totally on their own, it would take years to have done what AI did in a few days. Scott Hanton ** 15:13 The AI technology is amazing and powerful, but it's not new. No, I met a person who shared her story about AI investigations and talked about what she was doing in this field 30 years ago. Yeah, in her master's work. And you know, I knew it wasn't brand new, but I didn't really realize how deep its roots went until I talked to her. Michael Hingson ** 15:37 I worked as my first jobs out of college with Ray Kurzweil, who, of course, nowadays, is well known for the singularity and so on. But back then, he developed the first reading machine that blind people could use to read printed material. And one of the things that he put into that machine was the ability, as it scanned more material, to learn and better recognize the material. And so he was doing machine learning back in the 1970s Scott Hanton ** 16:07 right? And all of this is, you know, as Newton said on the shoulders of giants, right, right? He said it a bit cynically, but it's still true that we all in science, we are learning from each other. We're learning from the broader community, and we're integrating that knowledge as we tackle the challenges that we are exploring. Michael Hingson ** 16:27 So what got you to go into chemistry when you went into college? Scott Hanton ** 16:33 That's a good question. So when I was 13 years old, I went on a youth a church group youth trip to another city, and so they split us up, and there were three of us from our group that stayed overnight in a host family. And at dinner that night, the father worked in a pharmaceutical company, and he talked about the work he was doing, and what he was doing was really synthetic chemistry around small molecule drug discovery. And for me, it was absolutely fascinating. I was thrilled at that information. I didn't know any scientists growing up, I had no adult input other than teachers about science, and I can remember going back home and my parents asking me how the trip went. And it's like, it's fantastic. I'm going to be a chemist. And they both looked at me like, what is that? How do you make money from it? How do you get that? My dad was a banker. My mom was a school teacher. They had no scientific background, but that that one conversation, such serendipity, right? One conversation when I was 13 years old, and I came home and said, I'm going to be a chemist, and I've never really deviated from that path. Did you have other siblings? Younger brother and another younger sister? Michael Hingson ** 17:54 Okay? Did they go into science by any remote chance? Scott Hanton ** 17:58 Not at all. So they were both seventh grade teachers for more than 30 years. So my brother taught math and English, and my sister teaches social studies. Michael Hingson ** 18:10 Well, there you go. But that is also important. I actually wanted to teach physics, but jobs and other things and circumstances took me in different directions, but I think the reality is that I ended up going into sales. And what I realized, and it was partly because of a Dale Carnegie sales course I took, but I realized that good sales people are really teachers, because they're really teaching people about products or about things, and they're also sharp enough to recognize what their products might or might not do to help a customer. But that, again, not everyone does that, but so I figure I still was teaching, and today, being a public speaker, traveling the world, talking, of course, about teamwork and other things, it's still all about teaching. Scott Hanton ** 18:57 I think I've always been a teacher, and if you talk to my coworkers along the way, I enjoy helping people. I enjoy sharing my knowledge. There's always been a teacher inside but only in this job as the editorial director at lab manager have I really been able to do it directly. So we've developed what we call the lab manager Academy, and I create e learning courses to help lab managers be more successful, and it's been a passion project for me, and it's been a load of fun. Michael Hingson ** 19:30 And it doesn't get better than that. It's always great when it's a load of fun, yes, Scott Hanton ** 19:35 well, so you left college and you got a bachelor's and a master's degree, right? No masters for me, that step you went right to the old PhD, yeah. So I went straight. I went graduated from Michigan State. So Michigan State was on terms back in those days. So graduated in June, got married in July, moved to Wisconsin in August. To graduate school at the end of August at the University of Wisconsin. Okay? And my second year as a graduate student, my professor asked me, Do you want to stop and complete a master's? And I said, Wait, tell me about this word stop. And he said, Well, you'd have to finish the Master's requirements and write a thesis, and that's going to take some time. And I said, Do I have to and he said, No, and I don't recommend it. Just keep going forward and finish your PhD. So that's Michael Hingson ** 20:30 and what does your wife do? Scott Hanton ** 20:33 So my wife also is in the graduate program at the University of Wisconsin, and she decided that a master's degree was the right answer for her, because she didn't want to be a PhD scientist in XYZ narrow band of science. She wanted to be a master of chemistry. Okay, and so we took different paths through graduate school, but each of us took the path that worked best for us, and each pass has great value, so we're both happy with the choices that we made, Michael Hingson ** 21:06 and complement each other and also give you, still lots of great things to talk about over dinner. Scott Hanton ** 21:12 Absolutely. And she took that master's degree, went into the pharmaceutical industry and largely behaved as a librarian in her first part of her career, she wasn't called a librarian, but what she really did was a lot of information integrating, and then moved into the Library Group, and was a corporate librarian for a long time, and then a community librarian. So that path worked brilliantly for her. She also has a Masters of Library Science. So I have one PhD. She has two Master's degree. I have one bachelor's degree. She has two bachelor's degree. Michael Hingson ** 21:50 Oh, so you can have interesting discussions about who really progressed further, 21:54 absolutely. Michael Hingson ** 21:57 Well, that's, that's, that's cute, though. Well, I I got my bachelor's and master's. My wife, who I didn't meet until years later, wanted to be a librarian, but she ended up getting a a Master's at USC in so in sociology and and ended up getting a teaching credential and going into teaching, and taught for 10 years, and then she decided she wanted to do something different, and became a travel agent, which she had a lot of fun with. That is different, it is, but she enjoyed it, and along the way, then we got married. It was a great marriage. She was in a wheelchair her whole life. So she read, I pushed, worked out well, complimentary skills, absolutely, which is the way, way it ought to be, you know, and we had a lot of fun with it. Unfortunately, she passed now two and a half years ago, but as I tell people, we were married 40 years, and I'm sure she's monitoring me from somewhere, and if I misbehave, I'm going to hear about it, so I try to just behave. Sounds like good advice. Yeah, probably certainly the safe way to go. But we, we, we had lots of neat discussions, and our our activities and our expertise did, in a lot of ways, complement each other, so it was a lot of fun. And as I said, she went to USC. I enjoyed listening to USC football because I thought that that particular college team had the best announcers in the business, least when when I was studying in Southern California, and then when we got married, we learned the the day we got married, the wedding was supposed to start at four, and it didn't start till later because people weren't showing up for the wedding. And we learned that everybody was sitting out in their cars waiting for the end of the USC Notre Dame game. And we knew that God was on our side when we learned that SC beat the snot out of Notre Dame. So there you go. Yeah. Yeah. Oh gosh, the rivalries we face. So what did you do after college? Scott Hanton ** 24:09 So did my PhD at the University of Wisconsin. And one of the nice things, a fringe benefit of going to a big, important program to do your PhD, is that recruiters come to you. And so I was able to do 40 different, four, zero, 40 different interviews on campus without leaving Madison. And one of those interviews was with a company called Air Products. And that worked out, and they hired me. And so we moved to Allentown, Pennsylvania to go to work. I went to work at Air Products and and Helen found a role in the pharmaceutical industry at Merck. And so we did that for a long time. I was initially a research expert, a PhD expert doing lasers and materials and analytical stuff. And over the years. I progressed up the ladder from researcher to supervisor to what did we call it, group head to Section Manager, to operations manager, and ultimately to General Manager. Michael Hingson ** 25:13 Well, at least being in Allentown, you were close to a Cracker Barrel restaurant. Yes, that is true. That was the closest to one to where we lived in New Jersey, so we visited it several times. That's how I know Scott Hanton ** 25:26 about it. Maybe we were there at the same time. Michael, maybe this isn't our first. It's Michael Hingson ** 25:31 very possible. But we enjoyed Cracker Barrel and enjoyed touring around Pennsylvania. So I should have asked, What prompted you to go to the University of Wisconsin to do your your graduate work, as opposed to staying in Michigan. So Scott Hanton ** 25:47 my advisor at Michigan State, our advisor at Michigan State, told us, here's the top five schools, graduate programs in chemistry, apply to them all. Go to the one you get into. And so I got into three. Helen got into two. The one that was the same was Wisconsin. So that's where we went, yeah? Michael Hingson ** 26:09 Well, then no better logic and argument than that. Scott Hanton ** 26:14 It was a great Madison. Wisconsin is a beautiful city. It one of the things I really liked about the chemistry program there then, and it's still true now, is how well the faculty get along together so many collaborative projects and just friendliness throughout the hallways. And yes, they are all competing at some level for grant support, but they get along so well, and that makes it for a very strong community, Michael Hingson ** 26:41 and it probably also means that oftentimes someone who's applying for something can enlist support from other people who are willing to help. Scott Hanton ** 26:50 And as a graduate student, it meant that I had more than one professor that I could go to my advisor. There was a whole group of advisors who ran joint group meetings and would give us advice about our work or our writing or our approach, or just because we needed a pep talk, because completing a PhD is hard. Yeah, right, so that community was really important to me, and it's something I took away that when I started my industrial career, I had seen the value of community, and I wanted to build stronger communities wherever I went, yeah. Michael Hingson ** 27:26 So what does a company, does air products do Scott Hanton ** 27:31 that's sort of in the name, right? They're an industrial gas company. Got some of their big, biggest products are taking air and separating it into its components of nitrogen, oxygen, oxygen, argon, whatever, right? But at that time, they also had a chemicals business and a semiconductor business, or electronics business. So there was a lot of chemistry going on, although a lot of my work colleagues were chemical engineers who were working on the gasses side of the business, we had significant number of chemistry, sorts material science, sorts of people who are working on the chemicals side. Now, over time, Air Products divested those businesses, and now it's much more of a true industrial gas company. But I had the opportunity to work in an integrated science company that did all sorts of things. Michael Hingson ** 28:23 Yeah, and as as we know, certainly a little helium never hurt anyone. Scott Hanton ** 28:30 No little helium, you know, raises people's spirits, it Michael Hingson ** 28:34 does and their voices, it does. I I've visited helium tanks many times at UC Irvine when they had liquid helium, which was certainly a challenge because of how cold it had to be. But occasionally we would open a valve and little cold but useful helium gas would escape Scott Hanton ** 28:56 very cold. Please be safe. Cryogens are are dangerous materials, and we gotta make sure we handle them with due respect. Michael Hingson ** 29:05 Yeah, well, we, we all did and and didn't take too many chances. So it worked out pretty well. So you stayed in Allentown and you stayed with Air Products for how long Scott Hanton ** 29:19 I was in Air Products for 20 years. So the analytical group that I was part of, we were about 92 or 93 people when I joined the company, when I just left after earning my PhD. After 20 years, that group was down to about 35 just progressive series of decisions that made the department smaller, and as the Department got smaller and smaller, we were worried about our abilities to sustain our work. And so a dear friend and a key colleague, Paula McDaniel, and I, worked to try to see what other kind of opportunities there were. Yeah. And so we reached out to a contract research organization called Intertech to see if they would be interested in maybe acquiring our analytical department. And when we called them, and by the way, we called them before we talked to our boss about it, she forgave us later, but when we called the guy on the end of the phone said, Wait a minute, let me get your file. And it's like, what you have a file on Air Products, analytical, really? Why? Well, it turned out that they had a file, and that they had an active Merger and Acquisition Group, and they wanted an integrated analytical department on the east coast of the US. And so we engaged in negotiation, and ultimately this analytical department was sold by Air Products to Intertech. So on Friday, we're a little cog in a giant engine of an global, international company, and our funding comes from Vice Presidents. And on Monday, we're a standalone business of 35 people, we need to write quotes in order to make money. So it was an enormous challenge to transition from a service organization to a business. But oh my goodness, did we learn a lot, Michael Hingson ** 31:13 certainly a major paradigm shift, Scott Hanton ** 31:18 and I was lucky that I lost the coin flip, and Paula won, and she said, I want to be business development director. And I said, thank God. So she went off to be the key salesperson, and Paula was utterly brilliant as a technical salesperson, and I became the operations manager, which allowed me to keep my hands dirty with the science and to work with the scientists and to build a system and a community that allowed us to be successful in a CRO world. Michael Hingson ** 31:49 So at that time, when you became part, part of them, the new company, were you or the standalone business? Were you working in lab? Still yourself? Scott Hanton ** 32:01 Yes. So I had the title Operations Manager and all of the scientific staff reported into me, but I was still the technical expert in some mass spectrometry techniques, particularly MALDI and also tough Sims, and so I still had hands on lab responsibility that I needed to deliver. And over time, I was able to train some people to take some of those responsibilities off. But when the weight of the world was particularly heavy, the place for me to go was in the lab and do some experiments. Michael Hingson ** 32:34 Yeah, still so important to be able to keep your hand in into to know and understand. I know I had that same sort of need being the manager of an office and oftentimes working with other people who were the engineers, coming from a little bit of a technical background as well. I worked to always make sure I knew all I could about the products that I was dealing with and selling, and my sales people who worked for me constantly asked, How come, you know, all this stuff, and we don't then, my response always was, did you read the product bulletin that came out last week? Or have you kept up on the product bulletins? Because it's all right there, whether I actually physically repaired products or not, I knew how to do it. And so many times when I was involved in working with some of our engineers, I remember a few times our field support people, and we were working out of New Jersey, and then in New York at the time, in the World Trade Center, we had some customers up at Lockheed Martin, up in Syria, Rochester, I think it was. And the guys would go up, and then they'd call me on the phone, and we'd talk about it, and between us, we came up with some bright ideas. And I remember one day, all of a sudden, I get this phone call, and these guys are just bouncing off the walls, because whatever it was that was going on between them and me, we figured it out, and they put it in play and made it work, and they were all just as happy as clams at high tide, which is the way it ought to Scott Hanton ** 34:13 be. It's great to work in a team that finds success. The longer I was in technical management, the more I enjoyed the success of the team. It didn't need to be my success anymore that helping the scientists be successful in their roles was truly satisfying, Michael Hingson ** 34:33 and that helped you, by definition, be more successful in your role. Scott Hanton ** 34:36 And no question, it could be seen as a selfish byproduct, but the fact is that it still felt really good. Michael Hingson ** 34:43 Yeah, I hear you, because I know for me, I never thought about it as I've got to be successful. It's we've got problems to solve. Let's do it together. And I always told people that we're a team. And I have told every salesperson. I ever hired. I'm not here to boss you around. You've convinced me that you should be able to sell our products, and sometimes I found that they couldn't. But I said my job is to work with you to figure out how I can enhance what you do, and what skills do I bring to add value to you, because we've got to work together, and the people who understood that and who got it were always the most successful people that I ever had in my teams. Scott Hanton ** 35:30 One of the things I strive to do as a leader of any organization is to understand the key strengths of the people on the team and to try to craft their roles in such a way that they spend the majority of their time executing their strengths. Yeah. I've also discovered that when I truly investigate poor performance, there's often a correlation between poor performance and people working in their weaknesses. Yeah, and if we can shift those jobs, change those roles, make change happen so that people can work more often in their strengths, then good things happen. Michael Hingson ** 36:07 And if you can bring some of your skills into the mix and augment what they do, so much the better. Scott Hanton ** 36:16 Yeah, because I'm just another member of the team, my role is different, but I need to also apply my strengths to the problems and be wary of my weaknesses, because as the leader of the organization, my words carried undue weight. Yeah, and if, if I was speaking or acting in a space where I was weak, people would still do what I said, because I had the most authority, and that was just a lose, lose proposition Michael Hingson ** 36:43 by any standard. And and when you, when you operated to everyone's strengths, it always was a win. Yep, which is so cool. So you went to Intertech, and how long were you there? Scott Hanton ** 36:57 I was at Intertech for 10 years, and work I can if you know, for any listeners out there who work in the CRO world, it is a tough business. It is a grind working in that business, yeah? So it was a lot of long hours and testy customers and shortages of materials and equipment that was a hard a hard a hard road to plow, Michael Hingson ** 37:22 yeah, yeah, it gets to be frustrating. Sometimes it's what you got to do, but it still gets to be frustrating gets to be a challenge. The best part Scott Hanton ** 37:32 for me was I had a great team. We had senior and junior scientists. They were good people. They worked hard. They fundamentally, they cared about the outcomes. And so it was a great group of people to work with. But the contract lab business is a tough business. Yeah, so when covid came, you know, the pandemic settles in, all the restrictions are coming upon us. I was tasked as the General Manager of the business with setting up all the protocols, you know, how are we going to meet the number of people this basing the masks, you know, how could we work with and we were essential as a lab, so we had to keep doing what we were doing. And it took me about a week to figure non stop work to figure out what our protocols were going to be, and the moment I turned them into my boss, then I got laid off. So what you want to do in a time of crisis is you want to let go of the the general manager, the safety manager, the quality manager and the Chief Scientist, because those are four people that you don't need during times of stress or challenge or crisis. On the plus side for me, getting laid off was a bad hour. It hurt my pride, but after an hour, I realized that all the things that I'd been stressing about for years trying to run this business were no longer my problem. Yeah, and I found that it was a tremendous weight lifted off my shoulders to not feel responsible for every problem and challenge that that business had. Michael Hingson ** 39:14 And that's always a good blessing when you when you figure that out and don't worry about the the issues anymore. That's a good thing. It was certainly Scott Hanton ** 39:25 good for me. Yeah, so I'm not going to recommend that people go get laid off. No world to get fired. But one problem that I had is because Paula and I worked to create that business, I sort of behaved like an owner, but was treated like an employee. And my recommendation to people is, remember, you're an employee, find some personal boundaries that protect you from the stress of the business, because you're not going to be rewarded or treated like an owner. Michael Hingson ** 39:58 Yeah, because you're not because. Or not. Scott Hanton ** 40:01 So I got laid off. It was in the height of the pandemic. So, you know, I'm too busy of a human being to sort of sit in a rocking chair and watch the birds fly by. That's not my style or my speed. So I started a consulting business, and that was a lot of fun. I really enjoyed doing the consulting work, but I learned something really important about myself, and that's that while I can sell and I can be an effective salesperson, I don't like selling, and as a company of one, when I didn't sell, I didn't make any money, yeah, and so I needed to figure out something else to do, because I really hated selling, and I wasn't doing it. I was procrastinating, and that made the business be unpredictable and very choppy Michael Hingson ** 40:51 in that company of one, that guy who was working for you wasn't really doing all that you wanted. Scott Hanton ** 40:56 Exactly the Yeah, you know me as the founder, was giving me as the salesman, a poor performance review was not meeting objectives. So I had a long time volunteer relationship with lab manager magazine. I had been writing articles for them and speaking for them in webinars and in conferences for a long time, probably more than 10 years, I would say, and they asked me as a consultant to produce a a to a proposal to create the lab manager Academy. So the the founder and owner of the the company, the lab X Media Group, you really saw the value of an academy, and they needed it done. They needed it done. They couldn't figure it out themselves. So I wrote the proposal. I had a good idea of how to do it, but I was new to consulting, and I struggled with, how do I get paid for this? And I had four ideas, but I didn't like them, so I slept on it, and in the morning I had a fifth, which said, hire me full time. I sent in the proposal. An hour later, I had a phone call. A week later, I had a job, so that worked out fantastic. And I've really enjoyed my time at lab manager magazine. Great people, fun work. It's really interesting to me to be valued for what I know rather than for what I can do. Yeah, Michael Hingson ** 42:23 the two relate. But still, it does need to be more about what you know, what you really bring, as opposed to what you can do, because what you can do in general probably is an offshoot of what you know. Scott Hanton ** 42:38 So this gives me the opportunity to help lots of people. So on the outside of the company, I'm writing articles, creating courses, giving talks to help lab managers. Because I was a lab manager for a long time, yeah, over 20 years, and I know what those challenges are. I know how hard that job is, and I know how many decisions lab managers need to make, and it's wonderful to be able to share my experience and help them, and I am motivated to help them. So was it hard? Oh, go ahead, on the inside, I'm literally an internal subject matter expert, and so I can coach and teach and help my colleagues with what's the science? What do lab managers really think? How do we pitch this so that it resonates with lab managers, and I think that helps make all of our products better and more successful. Michael Hingson ** 43:31 So was it hard? Well, I guess best way to put it is that, was it really hard to switch from being a scientist to being a lab manager and then going into being a subject matter expert and really out of the laboratory. So Scott Hanton ** 43:48 people ask me all the time, Scott, don't you miss being in the lab and doing experiments? And my answer is, I miss being in the lab. And I do miss being in the lab. You know, on very stressful days at Intertech, I'd go in the lab and I'd do an experiment, yeah, because it was fun, and I had more control over the how the experiment was run and what I would learn from it than I did running a business. But the flip side of that is, I do experiments all the time. What I learned as the general manager of a business was the scientific method works. Let's data hypothesis. Let's figure out how to test it. Let's gather data, and let's see if the hypothesis stands or falls. And we ran a business that way, I think, pretty successfully. And even now, in in media and publishing, we still run experiments all the time. And it's kind of funny that most of my editorial colleagues that I work with, they think my favorite word is experiment. My favorite word is still why, but we talk all the time now about doing experiments, and that was a new thing for them, but now we can do continual improvement more in a more dedicated way, and we do it a lot faster. Yeah, Michael Hingson ** 45:00 yeah. So what's the hardest thing you think about being a lab manager? Scott Hanton ** 45:06 I think the hardest thing about let me answer that with two. I'm not going to be able to narrow it down to one, so I'll give you two. The first one is you transform, maybe one day to the next, from really being in control of your science and working with whether it's animals or rocks or electrons or chemicals, whatever you're working with, having a great degree of knowledge and a lot of control, and the next day, you're hurting cats. And so it's about that transition from having control over your destiny to influencing people to get the work done, and working with people instead of working with experiments, that's really hard. The second is, as a lab manager, there's endless decisions, and so combating decision fatigue is a big deal, and everybody in the lab depends upon you for the decisions you make. And it's not that every decision has to be perfect, you know, that's just a different failure mode if you try to make perfect decisions, but every decision needs to be made promptly. And as a scientist, I could always make more data in order to make a better decision, but as a lab manager, I would often only have maybe 40 or 50% of the data I wanted, and a decision had to be made. And getting comfortable making decisions in the face of uncertainty is really hard. Michael Hingson ** 46:29 So certainly, being a lab manager or Well, dealing with managers in the way we're talking about it here, has to be very stressful. How do you how do you cope with the stress? Scott Hanton ** 46:42 So I think ways to cope with the stress successfully is, first of all, you've got to take care of yourself. You know, we've all flown on airplanes, and what is the safety person in the aisle or on the video? Do oxygen masks will fall from the ceiling, and what do we do with them? We put them on before we help somebody else, right? We all know that. But in the workplace, especially as a manager, it's hard to remember that as we care for our team and try and take care of our team, there might not be enough time or energy or capacity left to take care of ourselves, but if we don't fill that gas tank every day doing something, then we can't help our team. And so one way to deal with the stress is to make sure that you take care of yourself. So Michael Hingson ** 47:28 what do you do? How do you deal with that? So Scott Hanton ** 47:31 for me, ways that I can reinvigorate is one. I like being outside and get my hands dirty. So I'm not really a gardener, but I call myself a yard dinner. So I grow grass and I grow flowers, and I trim trees, and I want to go outside, and I want to see immediate return on my effort, and I want it to be better than when I started. And it's good if I have to clean from under my fingernails when I'm doing it. Another thing I like to do is I play all kinds of games I'm happy to play, sorry, with little kids, or I'll play complicated strategy games with people who want to sit at a table for three or four hours at a time. Yeah? And that allows my brain to spin and to work but on something completely different. Yeah. And another thing that's been important for me, especially when I was a lab manager is to be involved in youth coaching, so I coached kids soccer and basketball and baseball teams, and it's just beautiful to be out there on a field with a ball, with kids. And you know, the worries of the world just aren't there. The kids don't know anything about them. And it's fun to work with the ones who are really good, but it's equally fun to work with the ones who have never seen the ball before, and to help them do even the most basic things. And that kind of giving back and paying it forward, that sort of stuff fills my tank. Michael Hingson ** 48:51 Yeah, I empathize a lot with with that. For me, I like to read. I've never been much of a gardener, but I also collect, as I mentioned before, old radio shows, and I do that because I'm fascinated by the history and all the things I learned from what people did in the 2030s, 40s and 50s, being on radio, much Less getting the opportunity to learn about the technical aspects of how they did it, because today it's so different in terms of how one edits, how one processes and deals with sounds and so on, but it's but it's fun to do something just totally different than way maybe what your normal Job would be, and and I do love to interact with with people. I love to play games, too. I don't get to do nearly as much of it as I'd like, but playing games is, is a lot of fun, Scott Hanton ** 49:52 and I agree, and it it's fun, it's diverting, it's it helps me get into a flow so that I'm focused on. Me on one thing, and I have no idea how much time has gone by, and I don't really care. You know, people who play games with me might question this. I don't really care if I win or lose. Certainly I want to win, but it's more important to me that I play well, and if somebody plays better, good for Michael Hingson ** 50:14 them, great. You'll learn from it. Exactly. Do you play Scott Hanton ** 50:18 chess? I have played chess. I've played a lot of chess. What I've learned with chess is that I'm not an excellent I'm a good player, but not an excellent player. And when I run into excellent players, they will beat me without even breaking a sweat. Michael Hingson ** 50:34 And again, in theory, you learn something from that. Scott Hanton ** 50:37 What I found is that I don't really want to work that hard and yeah. And so by adding an element of chance or probability to the game, the people who focus on chess, where there are known answers and known situations, they get thrown off by the uncertainty of the of the flip the card or roll the dice. And my brain loves that uncertainty, so I tend to thrive. Maybe it's from my time in the lab with elements of uncertainty, where the chess players wilt under elements of uncertainty, and it's again, it's back to our strengths, right? That's something that I'm good at, so I'm gonna go do it. I've Michael Hingson ** 51:20 always loved Trivial Pursuit. That's always been a fun game that I enjoy playing. I Scott Hanton ** 51:25 do love Trivial Pursuit. I watch Jeopardy regularly. A funny story, when we moved into our new house in Pennsylvania, it was a great neighborhood. Loved the neighbors there. When we first moved in, they invited my wife and I to a game night. Excellent. We love games. We're going to play Trivial Pursuit. Awesome like Trivial Pursuit. We're going to play as couples. Bad idea, right? Let's play boys against the girls, or, let's say, random draws. No, we're playing as couples. Okay, so we played as couples. Helen and I won every game by a large margin. We were never invited back for game night. Yeah, invited back for lots of other things, but not game night. Michael Hingson ** 52:06 One of the things that, and I've talked about it with people on this podcast before, is that all too often, when somebody reads a question from a trivial pursuit card, an answer pops in your head, then you went, Oh, that was too easy. That can't be the right answer. So you think about it, and you answer with something else, but invariably, that first answer was always the correct answer. Scott Hanton ** 52:32 Yes, I'm I have learned to trust my intuition. Yeah. I learned, as a research scientist, that especially in talking to some of my peers, who are very dogmatic, very step by step scientists. And they lay out the 20 steps to that they felt would be successful. And they would do one at a time, one through 20. And that made them happy for me, I do one and two, and then I'd predict where that data led me, and I do experiment number seven, and if it worked, I'm off to eight. And so I they would do what, one step at a time, one to 20, and I'd sort of do 127, 1420, yeah. And that I learned that that intuition was powerful and valuable, and I've learned to trust it. And in my lab career, it served me really well. But also as a manager, it has served me well to trust my intuition, and at least to listen to it. And if I need to analyze it, I can do that, but I'm going to listen to it, Michael Hingson ** 53:31 and that's the important thing, because invariably, it's going to give you useful information, and it may be telling you not what to do, but still trusting it and listening to it is so important, I've found that a lot over the years, Scott Hanton ** 53:47 Malcolm Gladwell wrote a book called Blink, where he talks about the power of the subconscious, and his claim is that the subconscious is 100,000 times smarter than our conscious brain, and I think when we are trusting our intuition, we're tapping into that super computer that's in our skulls. If you want to learn more, read blank. It's a great story. Michael Hingson ** 54:10 I hear you. I agree. How can people learn to be better leaders and managers? Scott Hanton ** 54:18 So I think it's there's really three normal ways that people do this. One is the power of experiment, right? And I did plenty of that, and I made tons of errors. It's painful. It's irritating, trial and error, but I used to tell people at Intertech that I was the general manager because I'd made the most mistakes, which gave me the most opportunity to learn. It was also partly because a lot of my peers wanted nothing to do with the job. You know, they wanted to be scientists. Another way is we, we get coached and mentored by people around us, and that is awesome if you have good supervisors, and it's tragic if you have bad supervisors, because you don't know any better and you take for granted. That the way it's been done is the way it needs to be done, and that prevents us from being generative leaders and questioning the status quo. So there's problems there, too. And I had both good and bad supervisors during my career. I had some awful, toxic human beings who were my supervisors, who did damage to me, and then I had some brilliant, caring, empathetic people who raised me up and helped me become the leader that I am today. So it's a bit of a crap shoot. The third way is go out and learn it from somebody who's done it right, and that's why we generated the lab manager Academy to try to codify all the mistakes I made and what are the learnings from them? And when I'm talking with learners who are in the program, it's we have a huge positive result feedback on our courses. And what I talk to people about who take our courses is I'm glad you appreciate what we've put together here. That makes me feel good. I'm glad it's helping you. But when these are my mistakes and the answers to my mistakes, when you make mistakes, you need to in the future, go make some courses and teach people what the lessons were from your mistakes and pay it forward. Yeah. So I recommend getting some training. Michael Hingson ** 56:17 What's the difference between management and leadership? Scott Hanton ** 56:21 I particularly love a quote from Peter Drucker. So Peter Drucker was a professor in California. You may have heard of him before. Michael Hingson ** 56:29 I have. I never had the opportunity to meet him, but I read. Scott Hanton ** 56:34 I didn't either material. I've read his books, and I think he is an insightful human being, yes. So the quote goes like this, management is doing things right. Leadership is doing the right things. So as a technical manager, there's a bunch of things we have to get right. We have to get safety right. We have to get quality right. There's an accuracy and precision that we need to get right for our outcomes and our results. Those are management tasks, but leadership is about doing the right things. And the interesting thing about that definition is it doesn't require a title or a role or any level of authority. So anyone can be a leader if you're consistently doing the right things, you are exhibiting leadership, and that could be from the person sweeping the floors or the person approving the budget, or anyone in between. Michael Hingson ** 57:33 Yeah, I've heard that quote from him before, and absolutely agree with it. It makes a whole lot of sense. Scott Hanton ** 57:41 Other definitions that I've seen trying to distinguish management and leadership tend to use the words manage and lead, and I don't like definitions that include the words that they're trying to define. They become circular at some level. This one, I think, is clear about it, what its intention is, and for me, it has worked through my career, and so the separation is valuable. I have authority. I'm the manager. I have accountability to get some stuff right, but anyone can lead, and everyone can lead, and the organization works so much better when it's full of leaders Michael Hingson ** 58:21 and leaders who are willing to recognize when they bring something to the table, or if someone else can add value in ways that they can't, to be willing to let the other individual take the leadership position for a while. Scott Hanton ** 58:40 Absolutely, and you know that really comes down to building an environment and a culture that's supportive. And so Amy Edmondson has written extensively on the importance of psychological safety, and that psychological safety hinges on what you just said, right? If the guy who sweeps the floor has an observation about the organization. Do they feel safe to go tell the person in charge that this observation, and if they feel safe, and if that leader is sufficiently vulnerable and humble to listen with curiosity about that observation, then everybody benefits, yeah, and the more safe everyone feels. We think about emotion. Emotional safety is they anyone can bring their best self to work, and psychological safety is they can contribute their ideas and observations with no threat of retaliation, then we have an environment where we're going to get the best out of everybody, yeah, Michael Hingson ** 59:46 which is the way it it really ought to be. And all too often we don't necessarily see it, but that is the way it ought Scott Hanton ** 59:53 to be. Too many people are worried about credit, or, I don't know, worried about things that I don't see. Yeah, and they waste human potential, right? They they don't open their doors to hire anybody. They they judge people based on what they look like instead of who they are, or they box people in into roles, and don't let them flourish and Excel. And whenever you're doing those kinds of things, you're wasting human potential. And businesses, science and business are too hard to waste human potential. We need to take advantage of everything that people are willing to give. Yeah, Michael Hingson ** 1:00:33 we've been doing this for quite a while already today. So I'm going to ask as a kind of a last question, what, what advice do you want to leave for people to think about going forward in their lives and in their careers? Scott Hanton ** 1:00:48 So I was participating in a LinkedIn chat today where a professor was asking the question, what sort of advice would you wish you got when you were 21 Okay, so it was an interesting thread, and there was one contributor to the thread who said something I thought was particularly valuable. And she said, attitude matters. Attitude matters. We can't control what happens to us, but we can control how we deal with it and how we respond, right? And so I think if we can hold our attitude as our accountability, and we can direct our strengths and our talents to applying them against the challenges that the business or the science or the lab or the community faces, and we can go in with some positive attitude and positive desire for for change and improvement, and we can be vulnerable and humble enough to accept other people's ideas and to interact through discussion and healthy debate. Then everything's better. I also like Kelleher his quote he was the co founder of Southwest Airlines, and he said, when you're hiring, hire for attitude, train for skill. Attitude is so important. So I think, understand your attitude. Bring the attitude you want, the attitude you value, the attitude that's that's parallel to your core values. And then communicate to others about their attitude and how it's working or not working for them. Michael Hingson ** 1:02:31 And hopefully, if they have a positive or good enough attitude, they will take that into consideration and grow because of it absolutely Scott Hanton ** 1:02:41 gives everybody the chance to be the best they can be. Michael Hingson ** 1:02:47 Well, Scott, this has been wonderful. If people want to reach out to you, how can they do that? Scott Hanton ** 1:02:51 So LinkedIn is great. I've provided Michael my LinkedIn connection. So I would love to have people connect to me on LinkedIn or email. S Hanson at lab manager.com love to have interactions with the folks out there. Michael Hingson ** 1:03:08 Well, I want to thank you for spending so much time. We'll have to do more of this. Scott Hanton ** 1:03:13 Michael, I really enjoyed it. This was a fun conversation. It was stimulating. You asked good questio
APAC stocks traded with a mostly negative bias after a similar performance among global peers.European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 0.2% after the cash market closed with gains of 0.3%.FX markets are contained, EUR/USD sits on a 1.15 handle, USD/JPY maintains its footing above the 148 mark.Bund futures lacked direction overnight. Crude futures were little changed but held on to most of the prior day's spoils.Looking ahead, highlights include Spanish GDP Estimate, US Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from UK, Germany & US.Earnings from AstraZeneca, Barclays, Unite, L'Oreal, Air Liquide, Orange, Kering, Banca Generali, Terna, Endesa, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
European bourses are broadly in the green, alongside strength in US futures ahead of a busy earnings slate.USD is firmer, EUR/USD's descent continues as markets digest the EU-US trade agreement.USTs await data and a 7yr auction, Bunds are on the backfoot giving back some of the prior day's upside.Crude resumes upside while metals are hampered by the Dollar.Looking ahead, highlights include US JOLTS Job Openings, Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from the US, Earnings from Kering, Banca Generali, Terna, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
Die Wall Street tendiert zwar freundlich, mit überwiegend aber negativen Reaktionen auf Quartalzahlen. Die Aktien von Merck, Novo Nordisk, UnitedHealth, UPS, Whirlpool, Stanley Black &Decker, Royal Caribbean, Spotify und PayPal notieren nach den Zahlen alle teils deutlich schwächer. Aufwärts geht es nach den Ergebnissen lediglich bei Boeing, Procter & Gamble und Corning. Nach dem Closing melden Starbucks, Mondelez und Booking Holdings. Heute enden die Gespräche zwischen den USA und China in Stockholm. Die Wall Street geht davon aus, dass die Pause der zeitweise deutlich angehobenen Zölle von Washington um 90 Tage verlängert wird. Die Wall Street rechnet erst im Herbst mit einer Einigung. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram
Die Wall Street tendiert zwar freundlich, mit überwiegend aber negativen Reaktionen auf Quartalzahlen. Die Aktien von Merck, Novo Nordisk, UnitedHealth, UPS, Whirlpool, Stanley Black &Decker, Royal Caribbean, Spotify und PayPal notieren nach den Zahlen alle teils deutlich schwächer. Aufwärts geht es nach den Ergebnissen lediglich bei Boeing, Procter & Gamble und Corning. Nach dem Closing melden Starbucks, Mondelez und Booking Holdings. Heute enden die Gespräche zwischen den USA und China in Stockholm. Die Wall Street geht davon aus, dass die Pause der zeitweise deutlich angehobenen Zölle von Washington um 90 Tage verlängert wird. Die Wall Street rechnet erst im Herbst mit einer Einigung. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html
In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über die IBM-Schwäche T-Mobile's Mega-Cash-Flow und Hoffnung auf einen finalen Zoll-Deal zwischen Amerika und der EU. Außerdem geht es um SAP, Siemens Energy, GE Vernova, Microsoft, Service Now, Abivax, Porsche, Volkswagen, BMW, Mercedes-Benz, Merck, Bayer, BASF, Brenntag, DHL, Boeing, Siemens, Amazon, Gea Group, Knorr Bremse, Evonik, Puma, Campari, Remy Cointreau. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Story at-a-glance Merck's respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children
Justin Abrams is the founder and CEO of the Aryo Consulting Group. For the past 12 years Justin and his team have helped hundreds of organizations around the world…from some of the most iconic global companies like Sony and Merck to some of the newest, fastest growing companies…create inflection points that fuel remarkable growth. Justin specializes in helping companies stimulate flat or falling sales, and move away from tired old playbooks that “used to work.” Every sales leader has a responsibility to have modern approaches for modern sales challenges. And today, Justin joins us and shares how some of the most successful teams in the world do exactly that. This is a timely message as leaders make 2nd half adjustments for the 2025 year. You can connect with Justin on LinkedIn here. (https://www.linkedin.com/in/justin-abrams-aryo-consulting/) You can check out Aryo here (https://aryocg.com/). For video excerpts of this and other episodes of the Sales Leadership Podcast, check out Sales Leadership United Here. (https://www.patreon.com/c/SalesLeadershipUnited)
In this episode of Decoding Destiny: Navigating Breast Cancer with Genetic Insight, I'm joined by Dena Goldberg, board-certified genetic counselor and founder of Malibu Genetics. We talk about the critical role genetic counselors play in assessing breast cancer risk, and how genetic testing can guide treatment and preventive care. Dena also shares how she supports patients through the emotional impact of receiving test results—and how understanding your genetic risk can be both empowering and life-saving. We also look ahead at the future of genetic testing, including the promise of population screening and the ongoing push for more equitable access. Listen now to learn how genetic counseling can help you and your loved ones make informed, proactive decisions about breast cancer risk. Special thanks to AstraZeneca and Merck for making this episode possible.
Third week of July, what'd you miss in vet med?VetValue Connect LaunchArchway Pets' AcquisitionAnnual Bravecto ApprovalHill's new PresidentOhio approves eVCPRHelpful links:The Bird Bath substackVetValue Connect Pre-RegistrationVVCA - Virtual Veterinary Care In The USA: Interactive Telemedicine Map
In this episode, Michael D. Levitt sits down with Justin, founder of Aryo Consulting Group, to unpack small businesses' real-world challenges in today's fast-paced economy. With a track record of helping over 350 companies—ranging from scrappy startups to established enterprises—Justin brings practical insight into what works (and what doesn't) when scaling a business.
As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.Contextualizing the appetite for GLP-1s (0:46)Build, buy, acquire: How Novo Nordisk and Eli Lilly are meeting demand (04:05)The implications of Novo Nordisk's $16.5 billion Catalent acquisition (05:53)How to decide whether to acquire or outsource (07:23)Where in the world is GLP-1 manufacturing going next? (10:36)DTC, telehealth, and the future of GLP-1 channel strategy (13:16)How AI is driving pharma innovation at Novo Nordisk, Eli Lilly, Johnson & Johnson, and Merck (17:13)
Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co's Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee's Phase II eczema win; and a look at India's wave of licensing. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
Drs. Hope Rugo, Sheri Brenner, and Mikolaj Slawkowski-Rode discuss the struggle that health care professionals experience when terminally ill patients are suffering and approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a monthly podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm your host, Dr. Hope Rugo. I'm director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. On today's episode, we'll be exploring the complexities of grief and oncology and the struggle we experience as healthcare professionals when terminally ill patients are suffering. Our guests will discuss approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way, as outlined in their recently published article titled, “Oncology and Suffering: Strategies on Coping With Grief for Healthcare Professionals.” I'm delighted today to welcome Dr. Keri Brenner, a clinical associate professor of medicine, palliative care attending, and psychiatrist at Stanford University, and Dr. Mikołaj Sławkowski-Rode, a senior research fellow in philosophy in the Humanities Research Institute at the University of Buckingham, where he also serves as director of graduate research in p hilosophy. He is also a research fellow in philosophy at Blackfriars Hall at the University of Oxford and associate professor at the University of Warsaw. Our full disclosures are available in the transcript of this episode. Dr. Brenner and Dr. Sławkowski-Rode, thanks for being on the podcast today. Dr. Keri Brenner: Great to be here, Dr. Rugo. Thank you so much for that kind introduction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. It's a pleasure and an honor. Dr. Hope Rugo: So I'm going to start with some questions for both of you. I'll start with Dr. Brenner. You've spoken and written about the concept of suffering when there is no cure. For oncologists, what does it mean to attune to suffering, not just disease? And how might this impact the way they show up in difficult conversations with patients? Dr. Keri Brenner: Suffering is something that's so omnipresent in the work of clinical oncology, and I like to begin by just thinking about what is suffering, because it's a word that we use so commonly, and yet, it's important to know what we're talking about. I think about the definition of Eric Cassell, who was a beloved mentor of mine for decades, and he defined suffering as the state of severe distress that's associated with events that threaten the intactness of a person. And my colleague here at Stanford, Tyler Tate, has been working on a definition of suffering that encompasses the experience of a gap between how things are versus how things ought to be. Both of these definitions really touch upon suffering in a person-centered way that's relational about one's identity, meaning, autonomy, and connectedness with others. So these definitions alone remind us that suffering calls for a person-centered response, not the patient as a pathology, but the panoramic view of who the patient is as a person and their lived reality of illness. And in this light, the therapeutic alliance becomes one of our most active ingredients in care. The therapeutic alliance is that collaborative, trusting bond as persons that we have between clinician and patient, and it's actually one of the most powerful predictors of meaningful outcomes in our care, especially in oncologic care. You know, I'll never forget my first day of internship at Massachusetts General Hospital. A faculty lecturer shared this really sage insight with us that left this indelible mark. She shared, “As physicians and healers, your very self is the primary instrument of healing. Our being is the median of the medicine.” So, our very selves as embodied, relationally grounded people, that's the median of the medicine and the first most enduring medicine that we offer. That has really borne fruit in the evidence that we see around the therapeutic alliance. And we see this in oncologic care, that in advanced cancer, a strong alliance with one's oncologist truly improves a patient's quality of life, treatment adherence, emotional well-being, and even surpasses structured interventions like psychotherapeutic interventions. Dr. Hope Rugo: That's just incredibly helpful information and actually terminology as well, and I think the concept of suffering differs so much. Suffering comes in many shapes and forms, and I think you really have highlighted that. But many oncologists struggle with knowing what to do when patients are suffering but can't be fixed, and I think a lot of times that has to do with oncologists when patients have pain or shortness of breath or issues like that. There are obviously many ways people suffer. But I think what's really challenging is how clinicians understand suffering and what the best approaches to respond to suffering are in the best patient-centered and therapeutic way. Dr. Keri Brenner: I get that question a lot from my trainees in palliative care, not knowing what to do. And my first response is, this is about how to be, not about knowing what to do, but how to be. In our medical training, we're trained often how to think and treat, but rarely how to be, how to accompany others. And I often have this image that I tell my trainees of, instead of this hierarchical approach of a fix-it mentality of all we're going to do, when it comes to elements of unavoidable loss, mortality, unavoidable sufferings, I imagine something more like accompaniment, a patient walking through some dark caverns, and I am accompanying them, trying to walk beside them, shining a light as a guide throughout that darkness. So it's a spirit of being and walking with. And it's so tempting in medicine to either avoid the suffering altogether or potentially overidentify with it, where the suffering just becomes so all-consuming like it's our own. And we're taught to instead strike a balance of authentic accompaniment through it. I often teach this key concept in my palli-psych work with my team about formulation. Formulation is a working hypothesis. It's taking a step back and asking, “Why? Why is this patient behaving in this manner? What might the patient's core inner struggle be?” Because asking that “why” and understanding the nuanced dimensions of a patient's core inner struggle will really help guide our therapeutic interactions and guide the way that we accompany them and where we choose to shine that light as we're walking with them. And oftentimes people think, “Well Keri, that sounds so sappy or oversentimental,” and it's not. You know, I'm just thinking about a case that I had a couple months ago, and it was a 28-year-old man with gastric cancer, metastatic disease, and that 28-year-old man, he was actually a college Division I athlete, and his dad was an acclaimed Division I coach. And our typical open-ended palliative care questions, that approach, infuriated them. They needed to know that I was showing up confident, competent, and that I was ready, on my A-game, with a real plan for them to follow through. And so my formulation about them was they needed somebody to show up with that confidence and competence, like the Division I athletes that they were, to really meet them and accompany them where they were on how they were going to walk through that experience of illness. Dr. Hope Rugo: These kinds of insights are so helpful to think about how we manage something that we face every day in oncology care. And I think that there are many ways to manage this. Maybe I'll ask Dr. Sławkowski-Rode one question just that I think sequences nicely with what you're talking about. A lot of our patients are trying to think about sort of the bigger picture and how that might help clinicians understand and support patients. So, the whole concept of spirituality, you know, how can we really use that as oncology clinicians to better understand and support patients with advanced illness, and how can that help patients themselves? And we'll talk about that in two different ways, but we'll just start with this broader question. Dr. Mikołaj Sławkowski-Rode: I think spirituality, and here, I usually refer to spirituality in terms of religious belief. Most people in the world are religious believers, and it is very intuitive and natural that religious beliefs would be a resource that people who help patients with a terminal diagnosis and healthcare professionals who work with those patients appeal to when they try to help them deal with the trauma and the stress of these situations. Now, I think that the interesting thing there is that very often the benefit of appealing to a religious belief is misunderstood in terms of what it delivers. And there are many, many studies on how religious belief can be used to support therapy and to support patients in getting through the experience of suffering and defeating cancer or facing a terminal diagnosis. There's a wealth of literature on this. But most of the literature focuses on this idea that by appealing to religious belief, we help patients and healthcare practitioners who are working with them get over the fact and that there's a terminal diagnosis determining the course of someone's life and get on with our lives and engaging with whatever other pursuits we might have, with our job if we're healthcare practitioners, and with the other things that we might be passionate about in our lives. And the idea here is that this is what religion allows us to do because we sort of defer the need to worry about what's going to happen to us until the afterlife or some perspective beyond the horizon of our life here. However, my view is – I have worked beyond philosophy also with theologians from many traditions, and my view here is that religion is something that does allow us to get on with our life but not because we're able to move on or move past the concerns that are being threatened by illness or death, but by forming stronger bonds with these things that we value in our life in a way and to have a sense of hope that these will be things that we will be able to keep an attachment to despite the threat to our life. So, in a sense, I think very many approaches in the field have the benefit of religion upside down, as it were, when it comes to helping patients and healthcare professionals who are engaged with their illness and treating it. Dr. Hope Rugo: You know, it's really interesting the points that you make, and I think really important, but, you know, sometimes the oncologists are really struggling with their own emotional reactions, how they are reacting to patients, and dealing with sort of taking on the burden, which, Dr. Brenner, you were mentioning earlier. How can oncologists be aware of their own emotional reactions? You know, they're struggling with this patient who they're very attached to who's dying or whatever the situation is, but you want to avoid burnout as an oncologist but also understand the patient's inner world and support them. Dr. Keri Brenner: I believe that these affective, emotional states, they're contagious. As we accompany patients through these tragic losses, it's very normal and expected that we ourselves will experience that full range of the human experience as we accompany the patients. And so the more that we can recognize that this is a normative dimension of our work, to have a nonjudgmental stance about the whole panoramic set of emotions that we'll experience as we accompany patients with curiosity and openness about that, the more sustainable the work will become. And I often think about the concept of countertransference given to us by Sigmund Freud over 100 years ago. Countertransference is the clinician's response to the patient, the thoughts, feelings, associations that come up within us, shaped by our own history, our own life events, those unconscious processes that come to the foreground as we are accompanying patients with illness. And that is a natural part of the human experience. Historically, countertransference was viewed as something negative, and now it's actually seen as a key that can unlock and enlighten the formulation about what might be going on within the patient themselves even. You know, I was with a patient a couple weeks ago, and I found myself feeling pretty helpless and hopeless in the encounter as I was trying to care for them. And I recognized that countertransference within myself that I was feeling demoralized. It was a prompt for me to take a step back, get on the balcony, and be curious about that because I normally don't feel helpless and hopeless caring for my patients. Well, ultimately, I discovered through processing it with my interdisciplinary team that the patient likely had demoralization as a clinical syndrome, and so it's natural many of us were feeling helpless and hopeless also accompanying them with their care. And it allowed us to have a greater interdisciplinary approach and a more therapeutic response and deeper empathy for the patient's plight. And we can really be curious about our countertransferences. You know, a few months ago, I was feeling bored and distracted in a family meeting, which is quite atypical for me when I'm sharing serious illness news. And it was actually a key that allowed me to recognize that the patient was trying to distract all of us talking about inconsequential facts and details rather than the gravitas of her illness. Being curious about these affective states really allows us to have greater sustainability within our own practice because it normalizes that human spectrum of emotions and also allows us to reduce unconscious bias and have greater inclusivity with our practice because what Freud also said is that what we can't recognize and say within our own selves, if we don't have that self-reflective capacity, it will come out in what we do. So really recognizing and having the self-awareness and naming some of these emotions with trusted colleagues or even within our own selves allows us to ensure that it doesn't come out in aberrant behaviors like avoiding the patient, staving off that patient till the end of the day, or overtreating, offering more chemotherapy or not having the goals of care, doing everything possible when we know that that might result in medically ineffective care. Dr. Hope Rugo: Yeah, I love the comments that you made, sort of weaving in Freud, but also, I think the importance of talking to colleagues and to sharing some of these issues because I do think that oncologists suffer from the fact that no one else in your life wants to hear about dying people. They don't really want to hear about the tragic cases either. So, I think that using your community, your oncology community and greater community within medicine, is an important part of being able to sort of process. Dr. Keri Brenner: Yes, and Dr. Rugo, this came up in our ASCO [Education] Session. I'd love to double click into some of those ways that we can do this that aren't too time consuming in our everyday practice. You know, within palliative care, we have interdisciplinary rounds where we process complex cases. Some of us do case supervision with a trusted mentor or colleague where we bring complex cases to them. My team and I offer process rounds virtually where we go through countertransference, formulation, and therapeutic responses on some tough cases. You know, on a personal note, just last week when I left a family meeting feeling really depleted and stuck, I called one of my trusted colleagues and just for 3 minutes constructively, sort of cathartically vented what was coming up within me after that family meeting, which allowed me to have more of an enlightened stance on what to do next and how to be therapeutically helpful for the case. One of my colleagues calls this "friend-tors." They coined the phrase, and they actually wrote a paper about it. Who within your peer group of trusted colleagues can you utilize and phone in real time or have process opportunities with to get a pulse check on where what's coming up within us as we're doing this work? Dr. Hope Rugo: Yeah, and it's an interesting question about how one does that and, you know, maintaining that as you move institutions or change places or become more senior, it's really important. One of the, I think, the challenges sometimes is that we come from different places from our patients, and that can be an issue, I think when our patients are very religious and the provider is not, or the reverse, patients who don't have religious beliefs and you're trying to sort of focus on the spirituality, but it doesn't really ring true. So, Dr. Sławkowski-Rode, what resources can patients and practitioners draw on when they're facing death and loss in the absence of, or just different religious beliefs that don't fit into the standard model? Dr. Mikołaj Sławkowski-Rode: You're absolutely right that this can be an extremely problematic situation to be in when there is that disconnect of religious belief or more generally spiritual engagement with the situation that we're in. But I just wanted to tie into what Dr. Brenner was saying just before. I couldn't agree more, and I think that a lot of healthcare practitioners, oncologists in particular who I've had the pleasure to talk to at ASCO and at other events as well, are very often quite skeptical about emotional engagement in their profession. They feel as though this is something to be managed, as it were, and something that gets in the way. And they can often be very critical of methods that help them understand the emotions and extend them towards patients because they feel that this will be an obstacle to doing their job and potentially an obstacle also to helping patients to their full ability if they focus on their own emotions or the burden that emotionally, spiritually, and in other ways the illness is for the patient. They feel that they should be focusing on the cancer rather than on the patient's emotions. And I think that a useful comparison, although, you know, perhaps slightly drastic, is that of combat experience of soldiers. They also need to be up and running and can't be too emotionally invested in the situation that they're in. But there's a crucial difference, which is that soldiers are usually engaged in very short bursts of activity with the time to go back and rethink, and they often have a lot of support for this in between. Whereas doctors are in a profession where their exposure to the emotions of patients and their own emotions, the emotions of families of patients is constant. And I think that there's a great danger in thinking that this is something to be avoided and something to compartmentalize in order to avoid burnout. I think, in a way, burnout is more sure to happen if your emotions and your attachment to your patients goes ignored for too long. So that's just following up on Keri's absolutely excellent points. As far as the disconnect is concerned, that's, in fact, an area in which I'm particularly interested in. That's where my research comes in. I'm interested in the kinds of connections that we have with other people, especially in terms of maintaining bonds when there is no spiritual belief, no spiritual backdrop to support this connection. In most religious traditions, we have the framework of the religious belief that tells us that the person who we've lost or the values that have become undermined in our life are something that hasn't been destroyed permanently but something that we can still believe we have a deep connection to despite its absence from our life. And how do you rebuild that sense of the existence of the things that you have perceivably lost without the appeal to some sort of transcendent realm which is defined by a given religion? And that is a hard question. That's a question, I think, that can be answered partly by psychology but also partly by philosophy in terms of looking at who we are as human beings and our nature as people who are essentially, or as entities that are essentially connected to one another. That connection, I believe, is more direct than the mediation of religion might at first suggest. I think that we essentially share the world not only physically, it's not just the case that we're all here, but more importantly, the world that we live in is not just the physical world but the world of meanings and values that helps us orient ourselves in society and amongst one another as friends and foes. And it is that shared sense of the world that we can appeal to when we're thinking about retaining the value or retaining the connection with the people who we have lost or the people who are helping through, go through an experience of facing death. And just to finish, there's a very interesting question, I think, something that we possibly don't have time to explore, about the degree of connection that we have with other people. So, what I've just been saying is something that rings more true or is more intuitive when we think about the connections that we have to our closest ones. We share a similar outlook onto the world, and our preferences and our moods and our emotions and our values are shaped by life with the other person. And so, appealing to these values can give us a sense of a continued presence. But what in those relationships where the connection isn't that close? For example, given the topic of this podcast, the connection that a patient has with their doctor and vice versa. In what sense can we talk about a shared world of experience? Well, I think, obviously, we should admit degrees to the kind of relationship that can sustain our connection with another person. But at the same time, I don't think there's a clear cutoff point. And I think part of emotional engagement in medical practice is finding yourself somewhere on that spectrum rather than thinking you're completely off of it. That's what I would say. Dr. Hope Rugo: That's very helpful and I think a very helpful way of thinking about how to manage this challenging situation for all of us. One of the things that really, I think, is a big question for all of us throughout our careers, is when to address the dying process and how to do that. Dr. Brenner, you know, I still struggle with this – what to do when patients refuse to discuss end-of-life but they're very close to end of life? They don't want to talk about it. It's very stressful for all of us, even where you're going to be, how you're going to manage this. They're just absolutely opposed to that discussion. How should we approach those kinds of discussions? How do we manage that? How do you address the code discussion, which is so important? You know, these patients are not able to stay at home at end-of-life in general, so you really do need to have a code discussion before you're admitting them. It actually ends up being kind of a challenge and a mess all around. You know, I would love your advice about how to manage those situations. Dr. Keri Brenner: I think that's one of the most piercing and relevant inquiries we have within our clinical work and challenges. I often think of denial not as an all-or-nothing concept but rather as parts of self. There's a part of everyone's being where the unconscious believes it's immortal and will live on forever, and yet we all know intellectually that we all have mortality and finitude and transience, and that time will end. We often think of this work as more iterative and gradual and exposure based. There's potency to words. Saying, “You are dying within days,” is a lot higher potency of a phrase to share than, “This is serious illness. This illness is incurable. Time might be shorter than we hoped.” And so the earlier and more upstream we begin to have these conversations, even in small, subtle ways, it starts to begin to expose the patient to the concept so they can go from the head to the heart, not only knowing their prognosis intellectually but also affectively, to integrate it into who they are as a person because all patients are trying to live well while also we're gradually exposing them to this awareness of mortality within their own lived experience of illness. And that, ideally, happens gradually over time. Now, there are moments where the medical frame is very limited, and we might have short days, and we have to uptitrate those words and really accompany them more radically through those high-affective moments. And that's when we have to take a lot of more nuanced approaches, but I would say the more earlier and upstream the better. And then the second piece to that question as well is coping with our own mortality. The more we can be comfortable with our own transience and finitude and limitations, the more we will be able to accompany others through that. And even within my own life, I've had to integrate losses in a way where before I go in to talk to one of my own palliative care patients, one mantra I often say to myself is, “I'm just a few steps behind you. I don't know if it's going to be 30 days or 30 years, but I'm just a few steps behind you on this finite, transient road of life that is the human experience.” And that creates a stance of accompaniment that patients really can experience as they're traversing these tragedies. Dr. Hope Rugo: That's great. And I think those are really important points and actually some pearls, which I think we can take into the clinic. I think being really concrete when really the expected life expectancy is a few days to a couple of weeks can be very, very helpful. And making sure the patients hear you, but also continuing to let them know that, as oncologists, we're here for them. We're not abandoning them. I think that's a big worry for many, certainly of my patients, is that somehow when they would go to hospice or be a ‘no code', that we're not going to support them anymore or treat them anymore. That is a really important process of that as well. And of course, engaging the team makes a big difference because the whole oncology team can help to manage situations that are particularly challenging like that. And just as we close, I wanted to ask one last question of you, Dr. Brenner, that suffering, grief, and burnout, you've really made the point that these are not problems to fix but dimensions that we want to attend to and acknowledge as part of our lives, the dying process is part of all of our lives. It's just dealing with this in the unexpected and the, I think, unpredictability of life, you know, that people take on a lot of guilt and all sorts of things about, all sorts of emotions. And the question is now, people have listened to this podcast, what can they take back to their oncology teams to build a culture that supports clinicians and their team at large to engage with these realities in a meaningful and sustainable way? I really feel like if we could build the whole team approach where we're supporting each other and supporting the patients together, that that will help this process immeasurably. Dr. Keri Brenner: Yes, and I'm thinking about Dr. Sławkowski-Rode's observation about the combat analogy, and it made me recognize this distinction between suppression and repression. Repression is this unconscious process, and this is what we're taught to do in medical training all the time, to just involuntarily shove that tragedy under the rug, just forget about it and see the next patient and move on. And we know that if we keep unconsciously shoving things under the rug, that it will lead to burnout and lack of sustainability for our clinical teams. Suppression is a more conscious process. That deliberate effort to say, “This was a tragedy that I bore witness to. I know I need to put that in a box on the shelf for now because I have 10 other patients I have to see.” And yet, do I work in a culture where I can take that off the shelf during particular moments and process it with my interdisciplinary team, phone a friend, talk to a trusted colleague, have some trusted case supervision around it, or process rounds around it, talk to my social worker? And I think the more that we model this type of self-reflective capacity as attendings, folks who have been in the field for decades, the more we create that ethos and culture that is sustainable because clinician self-reflection is never a weakness, rather it's a silent strength. Clinician self-reflection is this portal for wisdom, connectedness, sustainability, and ultimately transformative growth within ourselves. Dr. Hope Rugo: That's such a great point, and I think this whole discussion has been so helpful for me and I hope for our audience that we really can take these points and bring them to our practice. I think, “Wow, this is such a great conversation. I'd like to have the team as a whole listen to this as ways to sort of strategize talking about the process, our patients, and being supportive as a team, understanding how we manage spirituality when it connects and when it doesn't.” All of these points, they're bringing in how we process these issues and the whole idea of suppressing versus sort of deciding that it never happened at all is, I think, very important because that's just a tool for managing our daily lives, our busy clinics, and everything we manage. Dr. Keri Brenner: And Dr. Rugo, it's reminding me at Stanford, you know, we have this weekly practice that's just a ritual where every Friday morning for 30 minutes, our social worker leads a process rounds with us as a team, where we talk about how the work that we're doing clinically is affecting us in our lives in ways that have joy and greater meaning and connectedness and other ways that might be depleting. And that kind of authentic vulnerability with one another allows us to show up more authentically for our patients. So those rituals, that small 30 minutes once a week, goes a long way. And it reminds me that sometimes slowing things down with those rituals can really get us to more meaningful, transformative places ultimately. Dr. Hope Rugo: It's a great idea, and I think, you know, making time for that in everybody's busy days where they just don't have any time anymore is important. And you don't have to do it weekly, you could even do something monthly. I think there's a lot of options, and that's a great suggestion. I want to thank you both for taking your time out for this enriching and incredibly helpful conversation. Our listeners will find a link to the Ed Book article we discussed today, which is excellent, in the transcript of this episode. I want to thank you again, Dr. Brenner and Dr. Sławkowski-Rode, for your time and for your excellent thoughts and advice and direction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. Dr. Keri Brenner: Thank you. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at the education sessions from ASCO meetings and our deep dives on new approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Hope Rugo @hope.rugo Dr. Keri Brenner @keri_brenner Dr. Mikolaj Slawkowski-Rode @MikolajRode Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Keri Brenner: No relationships to disclose Dr. Mikolaj Slawkowski-Rode: No relationships to disclose
Carl Quintanilla and Jim Cramer covered all of the bases on a historic day for Nvidia: The chipmaker became the first company to achieve a $4 trillion valuation. Hear what Jim had to say about what's ahead for the stock. Also in focus: Apple's Jeff Williams to step down as COO, copper tariffs and what they could mean for Tesla, UnitedHealth and the DOJ, Merck's $10 billion deal to acquire Verona Pharma, President Trump's 200% pharma tariff threat. Squawk on the Street Disclaimer
S&P futures are pointing to a flat open today. Asian markets traded mixed today with Japan's Nikkei logging small gains, supported by resilience in manufacturing. The Hang Seng underperformed, as property and tech stocks lagged. European markets are trading higher, with the DAX and CAC leading gains. President Trump announced a 50% tariff on copper, set for late July or early August implementation, and proposed a 200% tariff on pharmaceuticals with a longer timeline. He ruled out extending the August 1 deadline, emphasizing his tough stance on trade while accusing BRICS nations of undermining the U.S. dollar and threatening an additional 10% tariff. Companies Mentioned: Apple, Starbucks, Merck, Verona Pharma, AES Corp
S&P Futures are positive this morning as the market are anticipating announcement on trade deals. Treasury Secretary Scott Bessent and the Director of the White House National Economic Council Kevin Hassett are being discussed as the top candidates to succeed Jerome Powell as the next Fed Chair. Key economic event today will be the Fed's Meeting Minutes from last months fed meeting. Merck announced a deal to takeover VRNA. Boeing is higher on upbeat news related to plane deliveries. On the earning front, AZZ to release after the close today, tomorrow morning, SMPL, CAG & DAL are scheduled to release.
Boosted tariffs on select countries didn't stop markets from rallying, which led the NDX to hit another new all-time high. Nvidia (NVDA) also reached a new milestone: $4 trillion in market cap, the first company to ever reach the number. Microsoft (MSFT) climbed to a new high off an upgrade from Oppenheimer. Merck (MRK) and Verona Pharma (VRNA) rallied after Merck shared plans to buy Verona for $10 billion. Marley Kayden takes investors through the trading session's top stories.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about
Celebrity psychic healer. Master jewelry alchemist. Light warrior mentor.In this mesmerizing episode recorded live from Spirit Fest USA - Dulles, we sit down with the multidimensional force that is Jimi Merck—an internationally recognized psychic healer, medical intuitive, clairvoyant, hypnotist, and visionary jewelry designer. From surviving a near-death experience as a child to designing sacred, energetically encoded jewelry seen on celebrities and spiritual leaders alike, Jimi shares his remarkable journey of awakening and purpose. His creations are more than jewelry—they're three-dimensional prayers, carved in sacred ratios, cast in palladium-infused silver, and embedded with universal healing stones to awaken our soul's memory. But that's just the beginning…In This Episode, You'll Discover:How ancient sacred symbology revealed itself to Jimi at age 16 and became a healing language of creation.Why his jewelry is more than art—it's a functional energy healing tool that helps the body detox and recalibrate.The story of his traumatic brain injury and resurrection, which activated his lifelong psychic abilities.His process for helping clients heal inherited trauma, unlock soul gifts, and remember who they truly are.What it means to be a “light warrior” and how Jimi trains others to step into their spiritual power.Why true healing begins with one essential act: radical self-love.About Jimi Merck Jimi is the founder of Shine Your Light Wellness, a platform offering remote psychic healing, intuitive guidance, and transformational coaching. Over the last 25 years, he has:Sold over 110,000 pieces of healing jewelry worldwideWorked with 12,000+ clients including athletes, celebrities, and politiciansTaught over a million students through workshops and live eventsMastered 30 healing modalities and studied 12 global shamanic traditionsHe's known for helping clients unlock their soul's potential in just one session—and for crafting sacred tools that awaken your spiritual DNA.Connect with Jimi Merck
In his weekly clinical update, Dr. Griffin with Vincent Racaniello are alarmed at how RFK is breaking his promise of not altering vaccine policies, and nonexistent data and studies are used by members of the ACIP to make changes to immunization practices in the absence of a CDC director, justification for not honoring the US commitment to GAVI and global public policies including support of routine childhood immunizations, placing millions of children at risk for the return of vaccine preventable diseases including polio outbreaks in Pappa New Guinea and increased circulation of wildtype type 1 poliovirus, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, approval of Merck's anti-RSV mRNA monoclonal antibody, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, immunization recommendations for COVID-19 vaccines, where to find PEMGARDA, changes in COVID mRNA vaccine labeling and reframing of the science around the vaccine, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Jake Scott (Stanford University) Vaccine Randomized control trials (Bradspellberg.com) Vaccine RCT spreadsheet aims to show the data, dispel myths about vaccines (CIDRAP) Vaccines-rcts (Bradspellberg.com) CDC's upcoming vaccine advisory meeting set up to sow distrust in vaccines (CIDRAP) Next ACIP meeting (CDC: ACIP) June meeting: MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) (CDC: ACIP agenda) Robert F Berman, PhD (UC Davis Health: Department of Neurological Surgery) Transparency = nonexistent data: CDC advisers appears to cite nonexistent study to support claims about risk of vaccine preservative (CNN) A C.D.C. Committee Just Voted Against Flu Shots With This Preservative. Is It Safe? (NY Times) CDC vaccine advisory committee to review long-approved immunizations (STAT News) Newly appointed CDC vaccine advisory committee holds first meeting, stirs more controversy (CIDRAP) FDA approves clesrovimab to protect infants during first RSV season (Contemporary Pediatrics) ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination (Contemporary Pediatrics) Susan Monarez (Wikipedia) Robert F Kennedy Jr (Wikipedia) Centers for Disease Control and Prevention (Wikipedia) Who is in charge at the CDC (CDC: About CDC) Do children REALLY need to be vaccinated? (Wall Street Journal) U.S. Adults' Views on Routine Childhood Vaccination (Harvard Opinion Research Program) RFK Jr. declares US withdrawal from GAVI (YouTube) Kennedy Withdraws U.S. Funding Pledge to International Vaccine Agency (NY Times) Millions of children at risk as global vaccine rates fall (Guardian) Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030 (LANCET) Polio this week: 47 WPV1 positive environmental samples this week! (GPEI) H5 bird flu: current situation (CDC: Avian Influenza) Cambodia logs fifth death from H5N1 avian flu as USDA weighs poultry vaccination (CIDRAP) Cambodia reports 6th H5N1 bird flu case this year(BNO News) USDA develops potential plan to vaccinate poultry for bird flu (Reuters) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles vaccine recommendations from NYP (jpg) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Novel Drug Approvals for 2025 (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) Episode 184: Fool's Gold: Reframing the Science…..reframing? (Apple Podcasts: Osterholm Update) Children with Post COVID-19 Multisystem Inflammatory Syndrome Display Unique Pathophysiological Metabolic Phenotypes (Journal of Proteome Research) FDA COVID mRNA vaccine labeling update (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Stellate Ganglion Block for the Treatment of COVID-19−Induced Parosmia (JAMA Otolaryngology-Head& Neck Surgery) Reaching out to US house representative Letters read on TWiV 1230 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
David Faber and Jim Cramer discussed he AI boom helping to boost the tech rally. Nvidia hitting a new all-time and surpassing Microsoft to become the world's most valuable company. Micron CEO Sanjay Mehrotra joined the program exclusively to discuss the role AI played in the chipmaker's better-than-expected earnings and upbeat guidance. Also in focus: Microsoft and Meta go after OpenAl for different reasons, Tesla vs. Waymo on robotaxis, McCormick's spicy earnings, Q1 GDP shrinks more than expected, RFK Jr.'s vaccine panel backs Merck's RSV shot for infants, Cramer's message on skyrocketing stocks and the "FOMO" trade. Squawk on the Street Disclaimer
Del and Jefferey dive into the troubling numbers behind Merck's new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.